

SUPERCONDUCTOR TECHNOLOGIES INC

Form S-1/A

December 08, 2016

[Table of Contents](#)

As filed with the Securities and Exchange Commission on December 8, 2016

Registration No. 333-214433

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Amendment No. 2 to
Form S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

SUPERCONDUCTOR TECHNOLOGIES INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware

3663

77-0158076

**(State or other jurisdiction of
incorporation or organization)**

**(Primary Standard Industrial
Classification Code Number)
9101 Wall Street, Suite 1300**

**(I.R.S. Employer
Identification No.)**

Austin, TX 78754

(512) 334-8900

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive
offices)**

Jeffrey A. Quiram

President and Chief Executive Officer

Superconductor Technologies Inc.

9101 Wall Street, Suite 1300

Austin, TX 78754

(512) 334-8900

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copy to:

**Ben D. Orlanski, Esq.
Matthew S. O Loughlin, Esq.
Manatt, Phelps & Phillips, LLP
11355 West Olympic Blvd.
Los Angeles, California 90064
(310) 312-4000
(310) 312-4224 Facsimile**

(Approximate date of commencement of proposed sale to the public) As soon as practicable after the effective date of this Registration Statement.

Edgar Filing: SUPERCONDUCTOR TECHNOLOGIES INC - Form S-1/A

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (Check one):

Large accelerated filer Accelerated filer
 Non-accelerated filer (Do not check if a smaller reporting company) Smaller reporting company

CALCULATION OF REGISTRATION FEE

Title of Each Class of Securities to be Registered	Proposed Maximum Aggregate Offering Price (1)	Amount of Registration Fee
Class A Units consisting of:		
(i) Common Stock, \$0.001 par value (2)		
(ii) Warrants to purchase Common Stock (3)		
Class B Units consisting of:		
(i) Series D Convertible Preferred Stock, \$0.001 par value		
(ii) Warrants to purchase Common Stock (3)		
Common Stock issuable upon conversion of Series D Convertible Preferred Stock (2)		
Common Stock issuable upon exercise of Warrants to purchase Common Stock (2)		
Total	\$20,000,000	\$2,318 (4)

- (1) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the Securities Act).
- (2) Pursuant to Rule 416 under the Securities Act, the securities being registered hereunder include such indeterminate number of additional shares of common stock as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions.
- (3) No additional registration fee is payable pursuant to Rule 457(g) under the Securities Act.
- (4) \$1,159 previously paid.

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine.

Table of Contents

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

SUBJECT TO COMPLETION, DATED DECEMBER 8, 2016

PRELIMINARY PROSPECTUS

2,118,650 Class A Units each consisting of one share of Common Stock and a Warrant

to purchase one share of Common Stock

5,000 Class B Units each consisting of \$1,000 of Series D Convertible Preferred Stock (convertible into 423.73 shares of Common Stock) and Warrants

to purchase 423.73 shares of Common Stock

(2,118,650 shares of Common Stock Underlying the Series D Convertible Preferred Stock

and 4,237,300 shares underlying the Warrants)

We are offering up to 2,118,650 shares of Class A Units (consisting of one share of our common stock and a warrant to purchase one share of our common stock at an exercise price equal to _____ % of the public offering price of the Class A Units). The shares of common stock and warrants part of a Class A Unit are immediately separable and will be issued separately in this offering.

We are also offering to those purchasers, if any, whose purchase of Class A Units in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding common stock immediately following the consummation of this offering, the opportunity, in lieu of purchasing Class A Units, to purchase Class B Units. Each Class B Unit will consist of one share of our Series D Convertible Preferred Stock, or the Series D Preferred, with a stated value of \$1,000 and convertible into 423.73 shares of our common stock at the public offering price of the Class A Units, together with the equivalent number of warrants as would have been issued to such purchaser if they had purchased Class A Units based on the public offering price. The stated conversion price assumes that the public offering price of the Class A Units is \$2.36, the reported closing price of our common stock on December 5, 2016. The Series D Preferred do not generally have any voting rights but are convertible into shares of common stock. The shares of Series D Preferred and warrants part of a Class B Unit are immediately separable and will be issued separately in this offering. The rights and obligations associated with Class A Units and Class B Units consist only in the constituent parts of each such unit, except that the Company has approved the sale of the constituent parts as units on the terms and conditions described in this prospectus.

We are also offering the shares of common stock that are issuable from time to time upon conversion of the Series D Preferred and upon exercise of the warrants being offered by this prospectus.

Assuming we sell all 2,118,650 Class A Units and 5,000 Class B Units in this offering at a public offering price of \$2.36 per Class A Unit, the reported closing price of our common stock on December 5, 2016, we would issue in this offering an aggregate of 2,118,650 shares of our common stock as part of the Class A Units, 5,000 shares of Series D Preferred as part of the Class B Units (convertible into 2,118,650 shares of common stock) and warrants to purchase 4,237,300 shares of our common stock.

Our common stock is currently listed on the NASDAQ Capital Market under the symbol **SCON**. On December 5, 2016, the reported closing price per share of our common stock was \$2.36. The Series D Preferred and the warrants will not be listed on any national securities exchange.

Investing in our securities involves a high degree of risks. See Risk Factors beginning on page 10 to read about factors you should consider before buying our securities.

Neither the Securities and Exchange Commission nor any state securities regulator has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

	Per Share	Per Class A Unit (one share of common stock and a warrant for one share of common stock)	Per Class B Unit (one share of Series D Preferred and a warrant for of a share of common stock)	Total
Public offering price	\$	\$	\$	\$
Placement agent's fees (1)	\$	\$	\$	\$
Proceeds, before expenses, to us	\$	\$	\$	\$

(1) We have agreed to reimburse the placement agent for certain of its expenses. See Plan of Distribution on page 30 of this prospectus for a description of the compensation payable to the placement agent.

Delivery of the securities will take place on or about _____, 2016, subject to satisfaction of certain conditions.

Rodman & Renshaw

a unit of H.C. Wainwright & Co.

The date of this prospectus is , 2016.

Table of Contents

Table of Contents

TABLE OF CONTENTS

	Page
<u>ABOUT THIS PROSPECTUS</u>	1
<u>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</u>	1
<u>PROSPECTUS SUMMARY</u>	3
<u>SUMMARY SELECTED CONSOLIDATED FINANCIAL INFORMATION</u>	8
<u>RISK FACTORS</u>	10
<u>USE OF PROCEEDS</u>	19
<u>CAPITALIZATION</u>	19
<u>DILUTION</u>	20
<u>PRICE RANGE OF COMMON STOCK</u>	22
<u>DIVIDEND POLICY</u>	22
<u>DESCRIPTION OF CAPITAL STOCK</u>	22
<u>DESCRIPTION OF SECURITIES WE ARE OFFERING</u>	28
<u>PLAN OF DISTRIBUTION</u>	30
<u>LEGAL MATTERS</u>	32
<u>EXPERTS</u>	32
<u>WHERE YOU CAN FIND MORE INFORMATION</u>	32
<u>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</u>	32

Table of Contents

ABOUT THIS PROSPECTUS

You should rely only on the information contained or incorporated by reference in this prospectus. We have not, and the placement agent has not, authorized any person to provide you with different or inconsistent information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not, and the placement agent is not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus and the documents incorporated by reference is accurate only as of their respective dates. Superconductor Technologies Inc.'s business, financial condition, results of operations and prospects may have changed since such dates.

We further note that the representations, warranties and covenants made by us in any document that is filed as an exhibit to the registration statement of which this prospectus is a part and in any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.

Unless the context otherwise requires, the terms Superconductor Technologies Inc., the Company, we, us, our and similar terms used in this prospectus refer to Superconductor Technologies Inc. and its subsidiaries.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains, and may incorporate by reference, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act. These forward-looking statements relate to future events or our future performance and include, but are not limited to, statements concerning our business strategy, future commercial revenues, market growth, capital requirements, new product introductions, expansion plans and the adequacy of our funding. Other statements contained in this prospectus that are not historical facts are also forward-looking statements. We have tried, wherever possible, to identify forward-looking statements by terminology such as may, will, could, should, expect, anticipate, intend plan, believe, seek, estimate and other comparable terminology. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections.

Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to:

our limited cash and a history of losses;

our need to materially grow our revenues from commercial operations and/or to raise additional capital (which financing may not be available on acceptable terms or at all) over the next 12-months to implement our current business plan and maintain our viability;

the performance and use of our equipment to produce wire in accordance with our timetable;

overcoming technical challenges in attaining milestones to develop and manufacture commercial lengths of our high temperature superconducting (HTS) wire;

the possibility of delays in customer evaluation and acceptance of our HTS wire;

the limited number of potential customers and customer pressures on the selling prices of our products;

the limited number of suppliers for some of our components and our HTS wire;

there being no significant backlog from quarter to quarter;

our market being characterized by rapidly advancing technology;

the impact of competitive products, technologies and pricing;

Table of Contents

manufacturing capacity constraints and difficulties;

the impact of any financing activity on the level of our stock price;

the dilutive impact of any issuances of securities to raise capital;

cost and uncertainty from compliance with environmental regulations; and

local, regional, and national and international economic conditions and events and the impact they may have on us and our customers.

We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. We caution investors that any forward-looking statements presented in this prospectus or the documents incorporated by reference herein or therein, or those that we may make orally or in writing from time to time, are based upon management's beliefs and assumptions and are made based on information available to us as of the time made and the actual outcome will be affected by known and unknown risks, trends, uncertainties and factors that are beyond our control or ability to predict. Although we believe that our assumptions are reasonable, they are not guarantees of future performance and some will inevitably prove to be incorrect. As a result, our actual future results can be expected to differ from our expectations, and those differences may be material. Accordingly, investors should use caution in relying on past forward-looking statements, which are based on known results and trends at the time they are made, to anticipate future results or trends.

Table of Contents

PROSPECTUS SUMMARY

This summary highlights information contained elsewhere or incorporated by reference into this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our securities. You should read this entire prospectus carefully, including the Risk Factors section contained in this prospectus, and our consolidated financial statements and the related notes and the other documents incorporated by reference into this prospectus.

Business Overview

We are a leading company in developing and commercializing high temperature superconductor (HTS) materials and related technologies. Superconductivity is the unique ability to conduct electricity with little or no resistance when cooled to critical temperatures. HTS materials are a family of elements that demonstrate superconducting properties at temperatures significantly warmer than previous superconducting materials. Electric currents that flow through conventional conductors encounter resistance that requires power to overcome and generates heat. HTS materials can substantially improve the performance characteristics of electrical systems, reduce power loss, and lowering heat generation providing extremely high current carrying density and zero resistance to direct current.

We were established in 1987 shortly after the discovery of HTS materials. Our stated objective was to develop products based on these materials for the commercial marketplace.

After analyzing the market opportunities available, we decided to develop products for the utility and telecommunications industries.

Our initial product was completed in 1998 and we began delivery to a number of wireless network providers. In the following 13 years, we continued to refine and improve the platform, with the primary focus on improving reliability, increasing performance and runtime, and most importantly, removing cost from the manufacturing process of the required subsystems. Our cost reducing efforts led to the invention of our proprietary, high-yield and high throughput HTS material deposition manufacturing process.

In late 2010, we transitioned our research and development efforts to adapting our proprietary HTS material deposition techniques to the production of our HTS Conductus[®] wire for next generation power applications, which is our primary opportunity to grow our future revenues. We continue to generate revenue from our legacy wireless communications products. This revenue has been declining and we expect this trend to continue until we completely abandon these products.

Our Proprietary Technology

Our development efforts over the last 28 years have yielded an extensive patent portfolio as well as critical trade secrets, unpatented technology and proprietary knowledge. We have an extensive patent portfolio in addition to critical trade secrets, unpatented technology and proprietary knowledge. Our current patents expire at various dates from 2016 to 2031. We enter into confidentiality and non-disclosure agreements with our employees, suppliers and consultants to protect our proprietary information.

Our strategic plan is to utilize our core proprietary technology in superconductivity and leverage our proprietary manufacturing processes to build Conductus wire for use in electrical power devices. We are adapting our unique HTS material deposition techniques to produce our energy efficient, cost-effective and high performance Conductus wire technology for next generation power applications. We have identified several large initial target markets for

superconducting wire including energy (wind turbines, cables, fault current limiters), medical (NMR (nuclear magnetic resonance) and MRI (magnetic resonance imaging)), science (high performance magnets) and industrial (motors, generators) applications. We are working with leading industry device manufactures to complete qualification and acceptance testing of Conductus wire. We expect to complete qualification orders of our commercial Conductus wire in early 2017.

Our development efforts (including those described under **Our Future Business** below) can take a significant number of years to commercialize, and we must overcome significant technical barriers and deal with other significant risks, some of which are set out in our public filings, including in particular the **Risk Factors** beginning on page 10 of this prospectus.

Table of Contents

Our Future Business

We have created several unique capabilities and HTS manufacturing systems related to our Conductus wire platform that we are seeking to produce by leveraging our leadership in superconducting technologies, extensive intellectual property and HTS manufacturing expertise.

HTS Wire Platform

Our Conductus wire product development is focused on large markets where the advantages of HTS wire are recognized by the industry. Our initial product roadmap targets three important applications: superconducting high power transmission cable, superconducting fault current limiters (SFCL) and high field magnets.

Superconducting High Power Transmission Cable: Superconducting high power transmission and distribution cable transmit 5 to 10 times the electrical current of traditional copper or aluminum cables with significantly improved efficiency. HTS power cable systems consist of the cable, which is comprised of 100 s of strands of HTS wire wrapped around a copper core, and the cryogenic cooling system to maintain proper operating conditions. HTS power cables are particularly suited to high load areas such as the dense urban business districts of large cities, where purchases of easements and construction costs for traditional low capacity cables may be cost prohibitive. The primary application for HTS cables is medium voltage feeds to load pockets in dense urban areas. In these high demand zones the grid is often saturated with aging infrastructure. HTS technology brings a considerable amount of power to new locations where the construction of additional transmission to distribution substations, with major transformer assets, is not feasible. Another potential use of HTS power cable is to improve grid power transmission by connecting two existing substations. In dense urban environments many substations often reach capacity limits and require redundant transformer capacity; to improve reliability HTS cables can tie these existing stations together, avoiding very costly transformer upgrades and construction costs.

Superconducting Fault Current Limiter (SFCL): With power demand on the rise and new power generation sources being added, the grid has become overcrowded and vulnerable to catastrophic faults. Faults are abnormal flows of electrical current like a short circuit. As the grid is stressed, faults and power blackouts increase in frequency and severity. SFCLs act like powerful surge protectors, preventing harmful faults from taking down substation equipment by reducing the fault current to a safer level (20 – 50% reduction) so that the existing switchgear can still protect the grid. Currently, electrical-utilities use massive 80kA circuit breakers, oversized transformers and fuses to prevent faults from damaging their equipment and protecting against surges. However, once a fault has occurred, standard circuit breakers suffer destructive failure and need to be replaced before service can be restored. In addition, Smart Grid and embedded alternative energy generation enhancements will increase the need for SCFLs. Grid operators face a major challenge in moving power safely and efficiently, from generators to consumers, through several stages of voltage transformation step downs and step ups. At each stage, valuable energy is lost in the form of waste heat. Moreover, while demands are continually rising, space for transformers and substations especially in dense urban areas is severely limited. Conventional oil-cooled transformers pose a fire and environmental hazard. Compact, efficient superconducting transformers, by contrast, are cooled by safe, abundant and environmentally benign liquid nitrogen. As an additional benefit, these actively-cooled devices will offer the capability of operating in overload, to twice the nameplate rating, without any loss of life to meet occasional utility peak load demands.

Superconducting High Field Magnets: There are a variety of applications that utilize superconducting magnets in order to capitalize on their unique ability to create extremely high magnetic fields. The NMR and MRI machines of today utilize such superconducting magnets for this very reason. Currently, high-field superconducting magnets are manufactured using commercially available superconducting wire such as niobium-titanium (NbTi) or niobium-tin (Nb₃Sn). NMR and MRI device manufacturers look towards advances in superconducting technologies to improve the overall performance of their systems by dramatically increasing the magnetic fields while reducing size. High demand for a robust, high performance and low cost superconducting wire has spurred rapid development of a next generation alternative. In the last 10 years, new second generation (2G) Rare Earth, Barium, Copper Oxide (ReBCO) superconducting materials have been proven to drastically increase magnetic field strengths, especially at low temperatures. These advanced ReBCO based superconductors now provide an excellent alternative to NbTi and Nb₃Sn based materials.

Table of Contents

Our Corporate Information

Our facilities and principal executive offices are located at 9101 Wall Street, Suite 1300, Austin, Texas 78754. Our telephone number is (512) 334-8900. We were incorporated in Delaware on May 11, 1987. Additional information about us is available on our website at www.suptech.com. The information contained on or that may be obtained from our website is not, and shall not be deemed to be, a part of this prospectus. Our common stock is currently traded on the NASDAQ Capital Market under the symbol **SCON**.

Risk Factors

An investment in our common stock involves certain risks. You should carefully consider the risks described under **Risk Factors** beginning on page 10 of this prospectus, as well as other information included or incorporated by reference into this prospectus, including our consolidated financial statements and the notes thereto, before making an investment decision.

Recent Developments

We have been selected as prime recipient of a \$4.5 million program award provided by the U.S. Department of Energy's Office of Energy Efficiency and Renewable Energy (EERE), on behalf of the Advanced Manufacturing Office, for its Next Generation Electric Machines program. Collaborating with the Company is TECO-Westinghouse Motor Company, an industry leading manufacturer of electric generators and motors, and renowned academic institutions Massachusetts Institute of Technology and University of North Texas. The award requires a \$1,125,000 million cost share from the Company and the collaborators.

The Company's selection does not constitute a commitment by the EERE to issue an award and the EERE's decision on whether and how to distribute federal funds is subject to the National Environmental Policy Act. All pre-award costs incurred by the Company will be incurred at the Company's own risk.

Table of Contents

The Offering

*The following summary contains basic information about the offering and the securities we are offering and is not intended to be complete. It does not contain all the information that is important to you. For a more complete understanding of the common stock, Series D Preferred, and the warrants, please refer to the sections of this prospectus titled *Description of Capital Stock* and *Description of Securities We Are Offering*.*

Class A Units offered by us

We are offering 2,118,650 Class A Units. Each Class A Unit will consist of one share of our common stock and a warrant to purchase one share of our common stock at an exercise price equal to _____ % of the public offering price of the Class A Units. The Class A Units will not be certificated and the share of common stock and warrants part of such unit are immediately separable and will be issued separately in this offering.

This prospectus also relates to the offering of shares of our common stock issuable upon the exercise of the warrants part of the Class A units.

Assuming we sell all 2,118,650 Class A Units and 5,000 Class B Units in this offering at a public offering price of \$2.36 per Class A Unit, the reported closing price of our common stock on December 5, 2016 and \$1,000 per Class B Unit, we would issue in this offering an aggregate of 2,118,650 shares of our common stock as part of the Class A Units, 5,000 shares of Series D Preferred as part of the Class B Units (convertible into 2,118,650 shares of common stock) and warrants to purchase 4,237,300 shares of our common stock.

Class B Units offered by us

We are also offering to those purchasers, if any, whose purchase of Class A Units in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% of our outstanding common stock immediately following the consummation of this offering, the opportunity, in lieu of purchasing Class A Units, to purchase Class B Units at an offering price equivalent to the Class A Units. Each Class B Unit will consist of one share of our Series D Convertible Preferred Stock, or the Series D Preferred, with a stated value of \$1,000 and convertible into 423.73 shares of our common stock at the public offering price of the Class A Units, together with the equivalent number of warrants as would have been issued to such purchaser if they had purchased Class A Units based on the public offering price. The stated conversion price assumes that the public offering price of the Class A Units is \$2.36, the reported closing price of our common stock on December 5, 2016. The Series D Preferred do not generally have any voting rights but are convertible into shares of common stock. The Class B Units will not be certificated and the share of Series D Preferred and warrants part of such unit are immediately separable and will be issued separately in this offering. The rights and obligations associated with Class A Units and Class B Units consist only in the constituent parts of each such unit, except that the Company has approved the sale of the constituent parts as units on the terms and

conditions described in this prospectus.

This prospectus also relates to the offering of shares of our common stock issuable upon conversion of the Series D Preferred Stock and upon exercise of the warrants part of the Class B Units.

Warrants

Each warrant included in the Units will have an exercise price equal to % of the public offering price of the Class A Units and shall have a term of exercise equal to .

Table of Contents

Common stock to be outstanding immediately after this offering	shares of common stock (1)(2)
Use of proceeds	We intend to use the net proceeds from the initial sale of the Units in this offering for working capital and general corporate purposes. General corporate purposes may include capital expenditures. See Use of Proceeds.
Market for our common stock	Our common stock is quoted and traded on the NASDAQ Capital Market under the symbol SCON.
No Market for the Series D Preferred or Warrants	There is no established public trading market for the warrants or the Series D Preferred, and we do not intend to apply to list the Series D Preferred or the warrants on any securities exchange or automated quotation system.

(1) The number of shares of common stock outstanding immediately after the closing of this offering is based on shares of common stock outstanding as of October 1, 2016, and, as of that date, excluded:

18,274 shares of our common stock issuable upon conversion of the 328,925 shares of outstanding Series A Convertible Preferred Stock, or Series A Preferred Stock (the conversion of our Series A Preferred Stock is subject to certain limitations. See Description of Capital Stock Preferred Stock Series A Convertible Preferred Stock on page 24 of this prospectus);

28,333 shares of our common stock issuable upon conversion of the 149 shares of outstanding Series B Convertible Preferred Stock, or Series B Preferred Stock (the conversion of our Series B Preferred Stock is subject to certain limitations. See Description of Capital Stock Preferred Stock Series B Convertible Preferred Stock on page 24 of this prospectus);

419,812 shares of our common stock issuable upon conversion of the 1,295 shares of outstanding Series C Convertible Preferred Stock, or Series C Preferred Stock (the conversion of our Series C Preferred Stock is subject to certain limitations. See Description of Capital Stock Preferred Stock Series C Convertible Preferred Stock on page 24 of this prospectus);

131,174 shares of our common stock issuable upon exercise of stock options under our stock plans at a weighted average exercise price of \$36.08 per share; and

2,600,388 shares of our common stock issuable upon exercise of warrants at a weighted average exercise price of \$8.84 per share. Of such warrants, an aggregate of 407,825 warrants originally issued in our August

2013 financing include a price adjustment mechanism whereby the exercise price of such warrants will be automatically reduced, subject to limitations, to the extent we issue shares of our common stock, or equivalents, at a price lower than the then applicable exercise price of such warrants which is currently \$3.00. Accordingly, any offering price of the Units less than \$3.00 per Unit will cause the exercise price of the warrants originally issued in our August 2013 financing to be to such price.

- (2) Excludes the shares of common stock that may be issued under the warrants to be issued in this offering. Assumes only Class A Units are sold in this offering. To the extent we sell any Class B Units, the same aggregate number of common stock equivalents resulting from this offering would be convertible under the Series D Preferred issued as part of the Class B Units.

Table of Contents**SUMMARY SELECTED CONSOLIDATED FINANCIAL INFORMATION**

You should read the summary selected consolidated financial information presented below in conjunction with the Management's Discussion and Analysis of Financial Condition and Results of Operations section and our consolidated financial statements and the notes to those consolidated financial statements appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, which is incorporated by reference in this prospectus.

The following tables set forth selected consolidated financial data at and for each of the years in the five-year period ended December 31, 2015 and at and for the nine-month periods ending October 1, 2016 and September 26, 2015.

The summary statements of operations data for the years ended December 31, 2015, 2014 and 2013, and the summary balance sheets data as of December 31, 2015 and 2014, have been derived from our audited consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, which is incorporated by reference in this prospectus. The summary statement of operations data for the years ended December 31, 2012 and 2011 and the summary balance sheet data as of December 31, 2013, 2012 and 2011 have been derived from our audited consolidated financial statements that are not included nor incorporated by reference into this prospectus.

	Nine months October 1, 2016 and September 26, 2015 (unaudited)		Years Ended December 31,				
	2016	2015	2015	2014	2013	2012	2011
(In thousands, except per share data)							
Statements of Operations Data:							
Net revenues:							
Net commercial product revenues	\$ 122	\$ 217	\$ 244	\$ 632	\$ 1,710	\$ 3,237	\$ 3,416
Government and other contract revenues						222	83
Total net revenues	122	217	244	632	1,710	3,459	3,499
Costs and expenses:							
Cost of commercial product revenues	2,796	2,238	3,004	1,558	1,051	3,850	5,434
Cost of government and other contract revenues						165	79
Other research and development	2,093	3,246	4,125	5,992	6,073	5,030	5,325
Selling, general and administrative	3,814	4,256	5,838	5,389	5,068	5,440	6,322
Total costs and expenses	8,703	9,740	12,967	12,939	12,192	14,485	17,160
Loss from operations	(8,581)	(9,523)	(12,723)	(12,307)	(10,482)	(11,026)	(13,661)
Other income (expense), net	(1)	3,320	4,121	4,056	(1,691)	98	278

Net loss	\$ (8,582)	\$ (6,203)	\$ (8,602)	\$ (8,251)	\$ (12,173)	\$ (10,928)	\$ (13,383)
Basic and diluted net loss per common share (1)	\$ (3.06)	\$ (5.80)	\$ (6.55)	\$ (9.67)	\$ (25.63)	\$ (50.14)	\$ (75.70)
Weighted average number of shares outstanding (1)	2,807	1,069	1,314	853	475	218	177

Table of Contents

	As of October 1, 2016 and September 26, 2015 (unaudited)			As of December 31,			
	2016	2015	2015	2014	2013	2012	2011
	(In thousands)						
Balance Sheets Data:							
Cash and cash equivalents	\$ 3,395	\$ 1,164	\$ 7,469	\$ 1,238	\$ 7,459	\$ 3,634	\$ 6,165
Working capital (deficit)	2,495	439	6,900	(407)	6,638	3,059	7,161
Total assets	8,569	8,659	14,365	10,799	14,840	12,029	12,949
Long-term debt, including current portion	1,025	1,034	400	5,624	6,263	674	628
Total stockholders equity	7,216	6,370	13,122	4,002	7,306	10,292	11,175

(1) All share and per share information has been adjusted as follows: for periods prior to March 11, 2013, retroactively adjusted to reflect the 1-12 reverse split of our common stock that was effective on March 11, 2013 and, for periods prior to July 18, 2016, retroactively adjusted to reflect a 1-for-15 reverse stock split of our common stock that was effective on July 18, 2016.

Table of Contents

RISK FACTORS

Investment in our securities involves a high degree of risk. You should carefully consider the risks described below, as well as those risks described in the sections titled Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations, each contained in our most recent Annual Report on Form 10-K for the year ended December 31, 2015, which has been filed with the SEC and is incorporated herein by reference in its entirety, as well as other information in this prospectus or in any other documents incorporated by reference. Each of the risks described in these sections and documents could adversely affect our business, financial condition, results of operations and prospects, and could result in a complete loss of your investment. This prospectus and the incorporated documents also contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks mentioned above.

Risks Related to Our Business

We have a history of losses and may never become profitable.

In each of our last five years, we have experienced significant net losses and negative cash flows from operations. In 2015, we incurred a net loss of \$8.6 million and had negative cash flows from operations of \$8.5 million. In 2014, we incurred a net loss of \$8.3 million and had negative cash flows from operations of \$10 million. Our independent registered public accounting firm has included in its audit reports an explanatory paragraph expressing substantial doubt about our ability to continue as a going concern. If we fail to increase our revenues, we may not achieve and may not maintain profitability, we may not realize our investment in infrastructure, and may not meet our expectations or the expectations of financial analysts who report on our stock.

We need to raise additional capital. If we are unable to raise capital our ability to implement our current business plan and ultimately our viability as a company could be adversely affected.

At October 1, 2016 and December 31, 2015, we had \$3.4 million and \$7.5 million, respectively, in cash and cash equivalents. While we completed an equity financing on August 2, 2016 which raised net proceeds of \$1.9 million, our current forecast is that our cash resources will not be sufficient to fund our business for the next 12-months. Therefore, unless we can materially grow our revenues from commercial operations prior to our cash reserves being depleted and generally over the next 12-months to implement our current business plan and maintain our viability, we will need to raise additional capital during the next 12-months to implement our current business plan and maintain our viability. Therefore, depending on the amount of capital we can raise in this offering and whether we can materially grow our revenues from commercial operations, we likely need to raise additional capital to implement our current business plan and maintain the viability of the Company.

We believe the key factors to our future liquidity will be our ability to successfully use our expertise and our technology to generate revenues in various ways, including commercial operations, joint ventures and licenses. Because of the expected timing and uncertainty of these factors, we will need to raise funds to meet our working capital needs.

Additional financing may not be available on acceptable terms or at all. If we issue additional equity securities to raise funds, the ownership percentage of our existing stockholders would be reduced. New investors may demand rights, preferences or privileges senior to those of existing holders of common stock and could also require that we issue warrants in connection with sales of our stock. If we cannot raise any needed funds to grow our commercial resources, we might be forced to make changes to, or delay aspects of, our business plan which could adversely affect our ability

to implement our current business plan and ultimately our viability as a company.

Our strategic initiative to develop a new wire platform may not prove to be successful.

We have spent a considerable amount of resources in developing a new wire platform for power applications. Substantial technical and business challenges remain before we can have a commercially successful product introduction. We may not be able to overcome these challenges in a timely or cost effective manner, if at all. Such a failure could adversely impact our prospects, liquidity, stock price and carrying value of our fixed assets.

Table of Contents

There are numerous technological challenges that must be overcome in order for our Conductus wire to become commercially successful and our ability to address such technological challenges may adversely affect our ability to gain customers.

We expect to begin commercial Conductus wire production in early 2017. Conductus® wire is uniquely positioned to address three key technical challenges in the market: high performance, improved economics and commercial-scale capacity. To date, we, along with existing HTS wire manufacturers, have not overcome these challenges to allow for broad commercialization of HTS wire. Customers cannot purchase long-length wire with any reasonable confidence or guaranteed volume; and electric utilities lack confidence in product availability which leads to delays in their deployment roadmap. HTS wire performance is currently below what many customers require. Many power applications require high performance wire with high current carrying capacity, mechanical durability, electrical integrity with low AC losses and minimal splices. Producing high performance HTS wire has proven difficult, especially at volumes required for large scale deployment. The high demand for high performance wire available in very low volume results in a high wire price that narrows the market and limits commercial viability. We are currently focused on improving our mechanical stress specifications to meet customer requirements for our target applications. We have made significant progress in this area, and our focus is now on using this new template stack to manufacture wire that delivers our customary power handling performance. Such delays and other delays in our Conductus wire development, as a result of technological challenges or other factors, may result in the introduction or commercial acceptance of our Conductus wire products later than expected.

The commercial uses of superconducting wire and superconducting wire related products are limited today, and a broad commercial market may not develop.

Even if the technological hurdles are overcome, there is no certainty that a robust commercial market for unproven HTS wire products will come to fruition. To date, commercial use of HTS wire has been limited to small feasibility demonstrations, and these projects are largely subsidized by government authorities. While customer demand is high and market forecasts project large revenue opportunity for superconducting wire in power applications, the market may not develop and superconducting wire might never achieve long term, broad commercialization. In such an event, we would not be able to commercialize our Conductus wire initiative and our business could be adversely impacted.

We have limited experience marketing and selling superconducting wire products, and our failure to effectively market and sell our superconducting wire solutions would lower our revenue and cash flow.

We have limited experience marketing and selling our Conductus wire. Once our Conductus wire is ready for commercial use, we will have to hire and develop a marketing and sales team to effectively demonstrate the advantages of our product over both more traditional products and competing superconducting products or other adjacent technologies. We may not be successful in our efforts to market this new technology.

We expect continued customer pressures to reduce our product pricing which may adversely affect our ability to operate on a commercially viable basis.

We expect to face pressure to reduce prices and accordingly, the average selling price of our Conductus wire. We anticipate customer pressure on our product pricing will continue for the foreseeable future. HTS wire is currently being sold at \$250/kiloampere-meter (kA-m). At this price, HTS wire represents more than half the cost of the end device. A price reduction is required for long term commercialization. Cryogenic systems, including cryocoolers and cryostats, have been developed but will also need to be cost optimized as HTS wire becomes available in volume. We have plans to further reduce the manufacturing cost of our products, but there is no assurance that our future cost reduction efforts will keep pace with price erosion. We will need to further reduce our manufacturing costs through

engineering improvements and economies of scale in production and purchasing in order to achieve adequate gross margins. We may not be able to achieve the required product cost savings at a rate needed to keep pace with competitive pricing pressure. Additionally, we may be forced to discount future orders or may never reach commercial viability. If we fail to reach our cost saving objectives or we are required to offer future discounts, our business may be harmed.

Table of Contents

We face competition with respect to various aspects of our technology and product development.

Our current wireless products compete on the basis of performance, functionality, reliability, pricing, quality, and compliance with industry standards. With respect to our Conductus wire materials, we compete with American Superconductor (AMSC), SuperPower (Furukawa), SuNam, Fujikura, Sumitomo and THEVA, among others. In addition, we currently supply components and license technology to several companies that may eventually decide to manufacture or design their own HTS components, rather than purchasing or licensing our technology. If we are unable to compete successfully against our current or future competitors, then our business and results of operations will be adversely affected.

We may not be able to compete effectively against alternative technologies.

Our products also compete with a number of alternative approaches and technologies. Some of these alternatives may be more cost effective or offer better performance than our products and we may not succeed in competing against these alternatives.

We currently rely on specific technologies and may not successfully adapt to the rapidly changing market environments.

We must overcome technical challenges to commercialize our Conductus wire. If we are able to do so, we will need to attain customer acceptance of our Conductus wire, and we cannot ensure that such acceptance will occur. We will have to continue to develop and integrate advances to our core technologies. We will also need to continue to develop and integrate advances in complementary technologies. We cannot guarantee that our development efforts will not be rendered obsolete by research efforts and technological advances made by others. Our business success depends upon our ability to keep pace with advancing technology, including materials, processes and industry standards.

We may experience significant fluctuations in sales and operating results from quarter to quarter.

Our quarterly results may fluctuate due to a number of factors, including:

the lack of any contractual obligation by our customers to purchase their forecasted demand for our products;

variations in the timing, cancellation, or rescheduling of customer orders and shipments; and

high fixed expenses that may disproportionately impact operating expenses, especially during a quarter with a sales shortfall.

Order deferrals and cancellations by our customers, declining average sales prices, changes in the mix of products sold, increases in inventory and finished goods, delays in the introduction of new products and longer than anticipated sales cycles for our products have, in the past, adversely affected our results of operations. If our customers desire to purchase products in excess of the forecasted amounts or in a different product mix, there may not be enough inventory or manufacturing capacity to fill their orders.

Due to these and other factors, our past results have limited predictive value as to our Conductus wire initiative. Future revenues and operating results may not meet the expectations of stock analysts and investors. In either case, the

price of our common stock could be materially adversely affected.

Worldwide economic uncertainty may adversely affect our business, operating results and financial condition.

The United States and global economies continue to experience a period of economic and financial uncertainty, which could result in economic volatility having direct and indirect adverse effects on our business, operating results and financial condition in a number of ways. For example, current or potential customers may delay or decrease spending with us, may delay paying us for previously purchased products, or may not pay us at all. In addition, this recent downturn has had, and may continue to have, an unprecedented negative impact on the global credit markets. If we are required to obtain financing in the near term to meet our working capital or other business needs, we may not be able to obtain that financing. Further, even if we are able to obtain the financing we need, it may be on terms that are not favorable to us, with increased financing costs and restrictive covenants.

Table of Contents

Our reliance on a limited number of suppliers and the long lead time of components for our products could impair our ability to manufacture and deliver our systems on a timely basis.

A number of components used in our products are available from a limited number of outside suppliers due to unique designs as well as certain quality and performance requirements. Our reliance on sole or limited source suppliers involves certain risks and uncertainties, many of which are beyond our control. These include the possibility of a shortage or the discontinuation of certain key components. Any reduced availability of these parts or components when required could impair our ability to manufacture and deliver our systems on a timely basis and result in the delay or cancellation of orders, which could harm our business.

In addition, the purchase of some of our key components involves long lead times and, in the event of unanticipated increases in demand for our solutions, we may be unable to obtain these components in sufficient quantities to meet our customers' requirements. We do not have guaranteed supply arrangements with any of these suppliers, do not maintain an extensive inventory of parts or components and customarily purchase sole or limited source parts and components pursuant to purchase orders. Business disruptions, quality issues, production shortfalls or financial difficulties of a sole or limited source supplier could materially and adversely affect us by increasing product costs, or eliminating or delaying the availability of such parts or components. In such events, our inability to develop alternative sources of supply quickly and on a cost-effective basis could impair our ability to manufacture and deliver our systems on a timely basis and could harm our business.

Our reliance on a limited number of suppliers exposes us to quality control issues.

Our reliance on certain single-source and limited-source components exposes us to quality control issues if these suppliers experience a failure in their production process or otherwise fail to meet our quality requirements. A failure in single-source or limited-source components or products could force us to repair or replace a product utilizing replacement components. If we cannot obtain comparable replacements or effectively return or redesign our products, we could lose customer orders or incur additional costs, which could have a material adverse effect on our gross margins and results of operations.

Our ability to protect our patents and other proprietary rights is uncertain, exposing us to possible losses of competitive advantage.

Our efforts to protect our proprietary rights may not succeed in preventing infringement by others or ensure that these rights will provide us with a competitive advantage. Pending patent applications may not result in issued patents and the validity of issued patents may be subject to challenge. Third parties may also be able to design around the patented aspects of the products. Additionally, certain of the issued patents and patent applications are owned jointly with third parties. Because any owner or co-owner of a patent can license its rights under jointly-owned patents or applications, inventions made by us jointly with others are not subject to our exclusive control. Any of these possible events could result in losses of competitive advantage.

We depend on specific patents and licenses to technologies, and we will likely need additional technologies in the future that we may not be able to obtain.

We utilize technologies under licenses of patents from others for our products. These patents may be subject to challenge, which may result in significant litigation expense (which may or may not be recoverable against future royalty obligations). Additionally, we continually try to develop new products, and, in the course of doing so, we may be required to utilize intellectual property rights owned by others and may seek licenses to do so. Such licenses may not be obtainable on commercially reasonable terms, or at all. It is also possible that we may inadvertently utilize

intellectual property rights held by others, which could result in substantial claims.

Intellectual property infringement claims against us could materially harm results of operations.

Our products incorporate a number of technologies, including high-temperature superconductor technology, technology related to other materials, and electronics technologies. Our patent positions, and that of other companies using high-temperature superconductor technology, is uncertain and there is significant risk that others, including our competitors or potential competitors, have obtained or will obtain patents relating to our products or technologies or products or technologies planned to be introduced by us.

Table of Contents

We believe that patents may be or have been issued, or applications may be pending, claiming various compositions of matter used in our products. We may need to secure one or more licenses of these patents. There can be no assurances that such licenses could be obtained on commercially reasonable terms, or at all. We may be required to expend significant resources to develop alternatives that would not infringe such patents or to obtain licenses to the related technology. We may not be able to successfully design around these patents or obtain licenses to them and may have to defend ourselves at substantial cost against allegations of infringement of third party patents or other rights to intellectual property. In those circumstances, we could face significant liabilities and also be forced to cease the use of key technology.

Other parties may have the right to utilize technology important to our business.

We utilize certain intellectual property rights under non-exclusive licenses or have granted to others the right to utilize certain intellectual property rights licensed from a third party. Because we may not have the exclusive rights to utilize such intellectual property, other parties may be able to compete with us, which may harm our business.

Because competition for target employees is intense, we may be subject to claims of unfair hiring practices, trade secret misappropriation or other related claims.

Companies in HTS wire industries whose employees accept positions with competitors frequently claim that competitors have engaged in unfair hiring practices, trade secret misappropriation or other related claims. We may be subject to such claims in the future as we seek to hire qualified personnel, and such claims may result in material litigation. If this should occur, we could incur substantial costs in defending against these claims, regardless of their merits.

Our success depends on the attraction and retention of senior management and technical personnel with relevant expertise.

As a competitor in a highly technical market, we depend heavily upon the efforts of our existing senior management and technical teams. The loss of the services of one or more members of these teams could slow product development and commercialization objectives. Due to the specialized nature of our products, we also depend upon our ability to attract and retain qualified technical personnel with substantial industry knowledge and expertise. Competition for qualified personnel is intense, and we may not be able to continue to attract and retain qualified personnel necessary for the development of our business.

Regulatory changes could substantially harm our business.

Certain regulatory agencies in the United States and other countries set standards for operations within their territories. HTS wire is subject to a regulatory regime, which may become more strictly regulated if the market grows. Any failure or delay in obtaining necessary approvals could harm our business.

We may acquire or make investments in companies or technologies that could cause loss of value to stockholders and disruption of business.

We may explore opportunities to acquire companies or technologies in the future. Other than the acquisition of Conductus, Inc. in 2002, we have not made any such acquisitions or investments to date and, therefore, our ability as an organization to make acquisitions or investments is unproven. An acquisition entails many risks, any of which could adversely affect our business, including:

failure to integrate operations, services and personnel;

the price paid may exceed the value eventually realized;

loss of share value to existing stockholders as a result of issuing equity securities to finance an acquisition;

potential loss of key employees from either our then current business or any acquired business;

Table of Contents

entering into markets in which we have little or no prior experience;

diversion of financial resources and management's attention from other business concerns;

assumption of unanticipated liabilities related to the acquired assets; and

the business or technologies acquired or invested in may have limited operating histories and may be subjected to many of the same risks to which we are exposed.

In addition, future acquisitions may result in potentially dilutive issuances of equity securities, or the incurrence of debt, contingent liabilities or amortization expenses or charges related to goodwill or other intangible assets, any of which could harm our business. As a result, if we fail to properly evaluate and execute acquisitions or investments, our business and prospects may be seriously harmed.

If we are unable to implement appropriate controls and procedures to manage our potential growth, we may not be able to successfully offer our products and implement our business plan.

Our ability to successfully offer our products and implement our business plan in a rapidly evolving market requires an effective planning and management process. Growth in future operations would place a significant strain on management systems and resources. We expect that we would need to improve our financial and managerial controls, reporting systems and procedures, and would need to expand, train and manage our work force worldwide. Furthermore, we expect that we would be required to manage multiple relationships with various customers and other third parties.

Compliance with environmental regulations could be especially costly due to the hazardous materials used in the manufacturing process. In addition, we could incur expenditures related to hazardous material accidents.

We are subject to a number of federal, state and local governmental regulations related to the use, storage, discharge and disposal of toxic, volatile or otherwise hazardous chemicals used in our business. Current or future laws and regulations could require substantial expenditures for preventative or remedial action, reduction of chemical exposure, waste treatment or disposal. Any failure to comply with present or future regulations could result in the imposition of fines, suspension of production or interruption of operations. In addition, these regulations could restrict our ability to expand or could require us to acquire costly equipment or incur other significant expense to comply with environmental regulations or to clean up prior discharges.

In addition, although we believe that our safety procedures for the handling and disposing of hazardous materials comply with the standards prescribed by state and federal regulations, there is always the risk of accidental contamination or injury from these materials. To date, we have not incurred substantial expenditures for preventive action with respect to hazardous materials or for remedial action with respect to any hazardous materials accident, but the use and disposal of hazardous materials involves risk that we could incur substantial expenditures for such preventive or remedial actions. If such an accident were to occur, we could be held liable for resulting damages. The liability in the event of an accident or the costs of such remedial actions could exceed our resources or otherwise have a material adverse effect on our financial condition, results of operations or cash flows.

The reliability of market data included in our public filings is uncertain.

Since we operate in a rapidly changing market, we have in the past, and may from time to time in the future, include market data from industry publications and our own internal estimates in some of the documents we file with the Securities and Exchange Commission. The reliability of this data cannot be assured. Industry publications generally state that the information contained in these publications has been obtained from sources believed to be reliable, but that its accuracy and completeness is not guaranteed. Although we believe that the market data used in our filings with the Securities and Exchange Commission is and will be reliable, it has not been independently verified. Similarly, internal company estimates, while believed by us to be reliable, have not been verified by any independent sources.

Table of Contents

Our international operations expose us to certain risks.

In 2007, we formed a joint venture with BAOLI to manufacture and sell our SuperLink interference elimination solution in China. In addition to facing many of the risks faced by our domestic business, if that joint venture or any other international operation we may have is to be successful, we (together with any joint venture partner) must recruit the necessary personnel and develop the facilities needed to manufacture and sell the products involved, learn about the local market (which may be significantly different from our domestic market), build brand awareness among potential customers and compete successfully with local organizations with greater market knowledge and potentially greater resources than we have. We must also obtain a number of critical governmental approvals from both the United States and the local country governments on a timely basis, including those related to any transfers of our technology. We must establish sufficient controls on any foreign operations to ensure that those operations are operated in accordance with our interests, that our intellectual property is protected and that our involvement does not inadvertently create potential competitors. There can be no assurance that these conditions will be met. Even if they are met, the process of building our international operations could divert financial resources and management attention from other business concerns. Finally, our international operations will also be subject to the general risks of international operations, such as:

changes in exchange rates;

international political and economic conditions;

changes in government regulation in various countries;

trade barriers;

adverse tax consequences; and

costs associated with expansion into new territories.

Risks Related to the Offering

Our stock price is volatile.

The market price of our common stock has been, and is expected to be, subject to significant volatility. The value of our common stock may decline regardless of our operating performance or prospects. Factors affecting our market price include:

our perceived prospects and liquidity;

progress or any lack of progress (or perceptions related to progress) in timely overcoming the remaining substantial technical and commercial challenges related to our Conductus wire initiative;

variations in our operating results and whether we have achieved key business targets;

changes in, or our failure to meet, earnings estimates;

changes in securities analysts' buy/sell recommendations;

differences between our reported results and those expected by investors and securities analysts;

announcements of new contracts by us or our competitors;

market reaction to any acquisitions, joint ventures or strategic investments announced by us or our competitors; and

general economic, political or stock market conditions.

Recent events have caused stock prices for many companies, including ours, to fluctuate in ways unrelated or disproportionate to their operating performance. The general economic, political and stock market conditions that may affect the market price of our common stock are beyond our control. The market price of our common stock at any particular time may not remain the market price in the future.

Table of Contents

If we fail to maintain the listing of our common stock with a U.S. national securities exchange, the liquidity of our common stock could be adversely affected.

Our ability to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we are delisted from the NASDAQ Capital Market or if we are unable to transfer our listing to another stock market.

Our common stock is listed for trading on the NASDAQ Capital Market. NASDAQ has adopted a number of continued listing standards that are applicable to our common stock, including a requirement that the bid price of our common stock be at least \$1.00 per share. Failure to maintain the minimum bid price can result in the delisting of our common stock from the NASDAQ Capital Market. We have previously fallen out of compliance with the minimum bid price requirement. On July 18, 2016 we effected a one-for-fifteen reverse stock split in connection with regaining compliance with the minimum bid requirement following a notice from the Listing Qualifications Department of the Nasdaq Stock Market on October 30, 2015 and received a notice of re-compliance from the Listing Qualifications Department of the Nasdaq Stock Market on August 2, 2016. We currently have approximately 3.7 million publicly held shares outstanding prior to this offering. Because of NASDAQ's continued listing standard which requires that we maintain at least 500,000 publicly held shares, our ability to effectuate a reverse split in the future is more limited than it has been in the past. Without taking into account the additional shares that would be issued in this offering, in the event we needed to effectuate an additional reverse split of our outstanding shares in order to satisfy NASDAQ's \$1.00 minimum bid price requirement, due to the 500,000 publicly held shares requirement, we would be limited to a reverse split ratio of not more than approximately 1 for 7 shares. Without taking into account the additional shares that would be issued in this offering, this effective limit to a reverse split ratio could prevent us from remediating a minimum bid price violation under circumstances where our stock price was substantially below \$1.00 and a higher ratio was needed to remediate the non-compliance. Although the additional shares that would be issued in this offering would tend to ameliorate this risk, we cannot predict the number of shares that will be issued in this offering, if any.

If our common stock is delisted by NASDAQ, our common stock may be eligible to trade on the OTC Bulletin Board, OTC QB or another over-the-counter market. Any such alternative would likely result in it being more difficult for us to raise additional capital through the public or private sale of equity securities and for investors to dispose of, or obtain accurate quotations as to the market value of, our common stock. In addition, there can be no assurance that our common stock would be eligible for trading on any such alternative exchange or markets.

Management will have broad discretion as to the use of the proceeds from this offering, and we may not use the proceeds effectively.

We have not designated the amount of net proceeds from this offering to be used for any particular purpose. Accordingly, our management will have broad discretion as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of this offering. Our stockholders may not agree with the manner in which our management chooses to allocate and spend the net proceeds. Moreover, our management may use the net proceeds for corporate purposes that may not increase our profitability or market value.

We have a significant number of outstanding warrants and options, and future sales of the shares obtained upon exercise of these options or warrants could adversely affect the market price of our common stock.

As of October 1, 2016, we had outstanding options exercisable for an aggregate of 72,046 shares of common stock at a weighted average exercise price of \$62.28 per share and warrants to purchase up to 2,600,388 shares of our common stock at a weighted average exercise price of \$8.84 per share. Of such warrants, an aggregate of 407,825 warrants originally issued in our August 2013 financing include a price adjustment mechanism whereby the exercise price of

such warrants will be automatically reduced, subject to limitations, to the extent we issue shares of our common stock, or equivalents, at a price lower than the then applicable exercise price of such warrants which is currently \$3.00. Accordingly, any offering price of the Units less than \$3.00 per Unit will cause the exercise price of the warrants originally issued in our August 2013 financing to be to such price. We have registered the issuance of all the shares issuable upon exercise of the options and warrants, and they will be freely tradable by the exercising party upon issuance. The holders may sell these shares in the public markets from time to time, without limitations on the timing, amount or method of sale. As our stock price rises, the holders may exercise their warrants and options and sell a large number of shares. This could cause the market price of our common stock to decline.

Our corporate governance structure may prevent our acquisition by another company at a premium over the public trading price of our shares.

It is possible that the acquisition of a majority of our outstanding voting stock by another company could result in our stockholders receiving a premium over the public trading price for our shares. Provisions of our restated certificate of incorporation and our amended and restated bylaws, each as amended, and of Delaware corporate law could delay or make more difficult an acquisition of our company by merger, tender offer or proxy contest, even if it would create an immediate benefit to our stockholders. For example, our restated certificate of incorporation does not permit stockholders to act by written consent, and our amended and restated bylaws generally require ninety days advance notice of any matters to be brought before the stockholders at an annual or special meeting.

Table of Contents

In addition, our board of directors has the authority to issue up to 2,000,000 shares of preferred stock and to determine the terms, rights and preferences of this preferred stock, including voting rights of those shares, without any further vote or action by the stockholders. At July 19, 2016, 1,383,727 shares of preferred stock remained unissued. The rights of the holders of common stock may be subordinate to, and adversely affected by, the rights of holders of preferred stock that may be issued in the future. The issuance of preferred stock could also make it more difficult for a third party to acquire a majority of our outstanding voting stock, even at a premium over our public trading price.

Further, our certificate of incorporation also provides for a classified board of directors with directors divided into three classes serving staggered terms. These provisions may have the effect of delaying or preventing a change in control of us without action by our stockholders and, therefore, could adversely affect the price of our stock or the possibility of sale of shares to an acquiring person.

We do not anticipate declaring any cash dividends on our common stock.

We have never declared or paid cash dividends on our common stock and do not plan to pay any cash dividends in the near future. Our current policy is to retain all funds and earnings for use in the operation and expansion of our business.

There is no public market for the Series D Convertible Preferred Stock or the warrants to purchase shares of our common stock being offered by us in this offering.

There is no established public trading market for the Series D Preferred Stock or the warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list the Series D Preferred Stock or the warrants on any national securities exchange or other nationally recognized trading system, including the NASDAQ Capital Market. Without an active market, the liquidity of Series D Preferred and the warrants will be limited.

You will experience immediate dilution in the book value per share of common stock as a result of this offering.

Investors in this offering will experience immediate dilution in their net tangible book value per share to the extent of the difference between the public offering price per share of common stock and the adjusted net tangible book value per share after giving effect to the offering. Our net tangible book value as of October 1, 2016 was approximately \$6.2 million, or \$1.89 per share of our common stock based on 3,276,782 shares outstanding. We are offering 2,118,650 Class A Units each consisting of one share of common stock and a warrant to purchase one share of common stock and 5,000 Class B Units each consisting of \$1,000 of Series D Convertible Preferred Stock (convertible into 423.73 shares of common stock) and warrants to purchase 423.73 shares of common stock. Assuming we issue all 2,118,650 Class A Units and all 5,000 Class B Units (and after giving effect to the 2,118,650 shares of common stock underlying the Series D Preferred) but excluding the common stock underlying the warrants issued with the Class A Units and the Class B Units), we would have initially issued the equivalent of 4,237,300 shares of common stock. Assuming that we issue \$10,000,028 of Class A and B Units at an assumed offering price of \$2.36 per Class A Unit and \$1,000 per Class B Unit, the closing price of our common stock on the NASDAQ Capital Market on December 5, 2016, and after deducting placement agents fees and estimated offering expenses payable by us, our net tangible book value as of October 1, 2016, would have been approximately \$15.2 million, or \$2.02 per share of our common stock. This calculation excludes the proceeds, if any, from the exercise of the warrants issued in this offering. This amount represents an increase in net tangible book value of \$0.13 per share to our existing stockholders and an immediate dilution in net tangible book value of \$0.34 per share to investors in this offering. See the section titled Dilution below.

Additional Risks Related to our Business, Industry and an Investment in our Common Stock

For a discussion of additional risks associated with our business, our industry and an investment in our common stock, see the section titled "Risk Factors" in our most recent Annual Report on Form 10-K, as filed with the SEC on March 30, 2016, as amended by Amendment No. 1 to our Annual Report on Form 10-K filed with the SEC on July 22, 2016, as well as the disclosures contained in documents filed by us thereafter pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act, which are incorporated by reference into, and deemed to be a part of, this prospectus.

Table of Contents**USE OF PROCEEDS**

We expect to receive net proceeds from the initial sale of the Units that we are offering to be approximately \$9 million, after deduction of placement agent fees and estimated expenses payable by us, as described in the section titled "Plan of Distribution" on page 30.

We currently intend to use the net proceeds from the initial sale of the Units in this offering for working capital and general corporate purposes. General corporate purposes may include capital expenditures. We will have significant discretion in the use of any net proceeds. Investors will be relying on the judgment of our management regarding the application of the proceeds of any sale of our common stock securities. We may invest the net proceeds temporarily until we use them for their stated purpose.

CAPITALIZATION

The following table sets forth our actual cash and cash equivalents and capitalization, each as of October 1, 2016, and as adjusted to give effect to the sale of the Units offered hereby and the use of proceeds, as described in the section titled "Use of Proceeds."

	As of October 1, 2016	
	Actual	As Adjusted (1)(2)
	(Dollars in thousands, except per share data)	
Cash and cash equivalents	\$ 3,395	\$ 12,395
Total Liabilities	\$ 1,353	\$ 1,353
Total stockholders' equity (3)		
Preferred stock, authorized 2,000,000 shares, \$0.001 par value per share; Series A Preferred Stock 328,925 issued and outstanding; Series B Preferred Stock 149 issued and outstanding; Series C Preferred Stock 1,295 issued and outstanding; Series D Preferred Stock issued and outstanding	\$	\$
Common stock, authorized 250,000,000 shares, \$0.001 par value; issued and outstanding 3,276,782, actual; issued and outstanding shares, as adjusted	3	8
Additional paid in capital	306,765	315,760
Retained earnings (accumulated deficit)	(299,552)	(299,552)
Total stockholders' equity	\$ 7,216	\$ 16,216
Total Capitalization	\$ 8,569	\$ 17,569

- (1) Assumes that \$10,000,028 of Class A Units are sold in this offering at an assumed offering price of \$2.36 per Class A Unit, the closing price of our common stock on the NASDAQ Capital Market on December 5, 2016 consisting of, in aggregate, 4,237,300 shares of our common stock and warrants to purchase 4,237,300 shares of our common stock, and that the net proceeds thereof are approximately \$9.0 million after deducting placement

agent fees and our estimated expenses. As of October 1, 2016, there were 3,276,782 shares of common stock outstanding. Assuming we issue all 2,118,650 Class A Units and all 5,000 Class B Units (and after giving effect to the 2,118,650 shares of common stock underlying the Series D Preferred) but excluding the common stock underlying the warrants issued with the Class A Units and the Class B Units), we would have initially issued the equivalent of 4,237,300 shares of common stock, and 7,514,082 shares of common stock will be outstanding immediately after the closing of this offering based on the number of shares of common stock outstanding as of October 1, 2016, and, as of that date.

- (2) Does not include the shares of common stock that may be issued under the warrants to be issued in this offering. Assumes only Class A Units are sold in this offering. To the extent we sell any Class B Units, the same aggregate number of common stock equivalents resulting from this offering would be convertible under the Series D Preferred issued as part of the Class B Units.

Table of Contents**DILUTION**

Our net tangible book value as of October 1, 2016 was approximately \$6.2 million, or \$1.89 per share of our common stock. Our net tangible book value per share represents our total tangible assets less total liabilities divided by the number of shares of our common stock outstanding on October 1, 2016. As of October 1, 2016, there were 3,276,782 shares of common stock outstanding. Assuming we issue all 2,118,650 Class A Units and all 5,000 Class B Units (and after giving effect to the 2,118,650 shares of common stock underlying the Series D Preferred) but excluding the common stock underlying the warrants issued with the Class A Units and the Class B Units), we would have initially issued the equivalent of 4,237,300 shares of common stock, and 7,514,082 shares of common stock will be outstanding immediately after the closing of this offering based on the number of shares of common stock outstanding as of October 1, 2016, and, as of that date. Assuming, for purposes of the table below, that we issue \$10,000,028 of Class A Units at an assumed offering price of \$2.36 per Class A Unit, the closing price of our common stock on the NASDAQ Capital Market on December 5, 2016, consisting of, in aggregate, 4,237,300 shares of common stock and warrants to purchase 4,237,300 shares of our common stock, and after deducting placement agents fees and estimated offering expenses payable by us, our net tangible book value as of October 1, 2016 would have been approximately \$15.2 million, or \$2.02 per share of our common stock. This calculation excludes the proceeds, if any, from the exercise of warrants issued in this offering. This amount represents an immediate increase in net tangible book value of \$0.13 per share to our existing stockholders and an immediate dilution in net tangible book value of \$0.34 per share to new investors purchasing shares of our common stock in this offering.

We determine dilution by subtracting the adjusted net tangible book value per share after this offering from the public offering price per share of our common stock. The following table illustrates the dilution in net tangible book value per share to new investors:

Assumed public offering price per Unit	\$ 2.36
Net tangible book value per share as of October 1, 2016	\$ 1.89
Increase per share attributable to new investors	\$ 0.13
Adjusted net tangible book value per share after this offering	\$ 2.02
Dilution in net tangible book value per share to new investors	\$ 0.34

If any shares of common stock are issued upon exercise of outstanding options, warrants or convertible securities, including the warrants issued in this offering, you may experience further dilution.

The information above is based on 3,276,782 shares outstanding as of October 1, 2016 and excludes the shares of common stock that may be issued under the warrants to be issued in this offering and also the following:

18,274 shares of our common stock issuable upon conversion of the 328,925 shares of outstanding Series A Convertible Preferred Stock, or Series A Preferred Stock (the conversion of our Series A Preferred Stock is subject to certain limitations. See Description of Capital Stock Preferred Stock Series A Convertible Preferred Stock on page 24 of this prospectus);

28,233 shares of our common stock issuable upon conversion of the 149 shares of outstanding Series B Convertible Preferred Stock, or Series B Preferred Stock (the conversion of our Series B Preferred Stock is subject to certain limitations. See Description of Capital Stock Preferred Stock Series B Convertible Preferred Stock on page 24 of this prospectus);

419,812 shares of our common stock issuable upon conversion of the 1,295 shares of outstanding Series C Convertible Preferred Stock, or Series C Preferred Stock (the conversion of our Series C Preferred Stock is subject to certain limitations. See Description of Capital Stock Preferred Stock Series C Convertible Preferred Stock on page 24 of this prospectus);

131,174 shares of our common stock issuable upon exercise of stock options under our stock plans at a weighted average exercise price of \$36.08 per share; and

2,600,388 shares of our common stock issuable upon exercise of warrants at a weighted average exercise price of \$8.84 per share. Of such warrants, an aggregate of 407,825 warrants originally issued in our August 2013 financing include a price adjustment mechanism whereby the exercise price of such warrants will be automatically reduced, subject to limitations, to the extent we issue shares of our common stock, or equivalents, at a price lower than the then applicable exercise price of such warrants which is currently \$3.00. Accordingly, any offering price of the Units less than \$3.00 per Unit will cause the exercise price of the warrants originally issued in our August 2013 financing to be to such price.

Table of Contents

The information above assumes only Class A Units are sold in this offering. To the extent we sell any Class B Units, the same aggregate number of common stock equivalents resulting from this offering would be convertible under the Series D Preferred issued as part of the Class B Units.

Table of Contents**PRICE RANGE OF COMMON STOCK**

Our common stock is listed and traded on the NASDAQ Capital Market under the symbol **SCON**. The following table sets forth, for the quarters shown, the range of high and low sales prices of our common stock on the NASDAQ Capital Market.

Quarter Ended	High	Low
2016		
Quarter ended December 31, 2016 (through December 5, 2016)	\$ 4.50	\$ 1.16
Quarter ended October 1, 2016	\$ 3.80	\$ 2.17
Quarter ended July 2, 2016	\$ 4.50	\$ 2.55
Quarter ended April 2, 2016	\$ 4.80	\$ 2.25
2015		
Quarter ended December 31, 2015	\$ 11.70	\$ 2.25
Quarter ended September 26, 2015	\$ 21.45	\$ 11.40
Quarter ended June 27, 2015	\$ 21.60	\$ 12.30
Quarter ended March 28, 2015	\$ 43.50	\$ 19.65
2014		
Quarter ended December 31, 2014	\$ 46.50	\$ 38.10
Quarter ended September 27, 2014	\$ 48.45	\$ 36.30
Quarter ended June 28, 2014	\$ 48.45	\$ 32.40
Quarter ended March 29, 2014	\$ 57.30	\$ 32.25

As of December 5, 2016, we had 3,724,927 shares of common stock outstanding, held by approximately 5,000 stockholders, including stockholders of record and beneficial owners. The last reported sales price of our common stock on the NASDAQ Capital Market on December 5, 2016 was \$2.36 per share.

DIVIDEND POLICY

We have never declared or paid cash dividends on our common stock and do not plan to pay any cash dividends in the near future. Our current policy is to retain all funds and earnings for use in the operation and expansion of our business. Payment of future dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs and plans for expansion.

DESCRIPTION OF CAPITAL STOCK

The following is a brief description of our capital stock. This summary does not purport to be complete in all respects. This description is subject to and qualified entirely by the terms of our restated certificate of incorporation, as amended, or our certificate of incorporation, and our amended and restated bylaws, or our bylaws, copies of which have been filed with the SEC and are also available upon request from us, and by the General Corporation Law of the State of Delaware.

Authorized Capitalization

We have 252,000,000 shares of capital stock authorized under our certificate of incorporation, consisting of 250,000,000 shares of common stock and 2,000,000 shares of preferred stock, of which 706,829 have been designated as Series A Convertible Preferred Stock, par value \$0.001 per share, or Series A Preferred Stock, 10,000 have been designated as Series B Convertible Preferred Stock, par value \$0.001 per share, or Series B Preferred

Table of Contents

Stock, and 1,500 have been designated as Series C Convertible Preferred Stock, par value \$0.001 per share, or Series C Preferred Stock. As of October 1, 2016, we had 3,276,782 shares of common stock, 328,925 shares of Series A Preferred Stock, 149 shares of Series B Preferred Stock and 1,295 shares of Series C Preferred Stock outstanding. Our authorized shares of common stock and preferred stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange or automated quotation system on which our securities may be listed or traded. If the approval of our stockholders is not so required, our board of directors may determine not to seek stockholder approval.

On July 18, 2016, we effected a 1-for-15 reverse stock split of our common stock, or the Reverse Stock Split. As a result of the Reverse Stock Split, every fifteen shares of our pre-Reverse Stock Split common stock were combined and reclassified into one share of our common stock. Previously, effective March 11, 2013, we effected a 1-for-12 reverse stock split of our common stock, or the March 2013 Reverse Stock Split. As a result of the March 2013 Reverse Stock Split, every twelve shares of our pre-March 2013 Reverse Stock Split common stock were combined and reclassified into one share of our common stock.

All share and per share data in this prospectus for periods prior to March 11, 2013 have been retroactively adjusted to reflect the 1-12 reverse split of our common stock that was effective on March 11, 2013 and, for periods prior to July 18, 2016, retroactively adjusted to reflect a 1-for-15 reverse stock split of our common stock that was effective on July 18, 2016.

Common Stock

Holders of our common stock are entitled to such dividends as may be declared by our board of directors out of funds legally available for such purpose, subject to any preferential dividend rights of any then outstanding preferred stock. The shares of common stock are neither redeemable nor convertible. Holders of common stock have no preemptive or subscription rights to purchase any of our securities.

Each holder of our common stock is entitled to one vote for each such share outstanding in the holder's name. No holder of common stock is entitled to cumulate votes in voting for directors.

In the event of our liquidation, dissolution or winding up, the holders of our common stock are entitled to receive pro rata our assets that are legally available for distribution, after payments of all debts and other liabilities and subject to the prior rights of any holders of preferred stock then outstanding. All of the outstanding shares of our common stock are fully paid and non-assessable. The shares of common stock offered by this prospectus and the shares of common stock underlying the warrants offered by this prospectus will be fully paid and non-assessable.

Our common stock is listed on the NASDAQ Capital Stock Market under the symbol **SCON**. Computershare is the transfer agent and registrar for our common stock. Its address is 250 Royall Street, Canton, MA 02021.

Preferred Stock

Our certificate of incorporation permits us to issue up to 2,000,000 shares of preferred stock in one or more series and with rights and preferences that may be fixed or designated by our board of directors without any further action by our stockholders. We currently have 706,829 shares of preferred stock designated as Series A Preferred Stock, 10,000 shares of preferred stock designated as Series B Preferred Stock and 1,500 shares of preferred stock designated as Series C Preferred Stock, of which, as of October 1, 2016, 328,925 shares of Series A Preferred, 149 shares of Series B Preferred and 1,295 shares of Series C Preferred were outstanding, respectively.

Subject to the limitations prescribed in our certificate of incorporation and under Delaware law, our certificate of incorporation authorizes the board of directors, from time to time by resolution and without further stockholder action, to provide for the issuance of shares of preferred stock, in one or more series, and to fix the designation, powers, preferences and other rights of the shares and to fix the qualifications, limitations and restrictions thereof. The issuance of preferred stock could adversely affect the rights of holders of our common stock, including with respect to voting, dividends and liquidation and, by issuing shares of preferred stock with certain voting, conversion and/or redemption rights. Such issuance of preferred stock may have the effect of delaying, deferring or preventing a change of control.

Table of Contents

Preferred stock could thus be issued quickly with terms calculated to delay or prevent a change in control of us or to make removal of management more difficult. Additionally, the issuance of preferred stock may decrease the market price of our common stock. The number of authorized shares of preferred stock may be increased or decreased, but not decreased below the number of shares then outstanding, by the affirmative vote of the holders of a majority of our common stock without a vote of the holders of preferred stock, or any series of preferred stock, unless a vote of any such holder is required pursuant to the terms of such series of preferred stock.

Series A Convertible Preferred Stock

In October 2007, in connection with entering into an amended investment agreement with Hunchun BaoLi Communication Co. Ltd., or BAOLI, our board of directors authorized the designation and issuance of 706,829 shares of Series A Preferred Stock. The terms of the investment agreement were subsequently amended and, in February 2008, we issued to BAOLI and two related purchasers (collectively, BAOLI), a total of approximately 17,230 shares of our common stock and 611,523 shares of our Series A Preferred Stock (convertible under certain conditions into approximately 33,974 shares of our common stock).

Subject to the terms and conditions of our Series A Preferred Stock and to customary adjustments to the conversion rate, shares of our Series A Preferred Stock are convertible into shares of our common stock so long as the number of shares of our common stock beneficially owned by BAOLI following such conversion does not exceed 9.9% of our outstanding common stock. Except for a preference on liquidation of \$0.01 per share, each share of Series A Preferred Stock is the economic equivalent of the ten shares of common stock into which it is convertible. Except as required by law, the Series A Preferred Stock will not have any voting rights. For a complete description of the terms of the Series A Preferred Stock, please see the certificate of designations, which is incorporated by reference into the registration statement of which this prospectus is a part.

Series B Convertible Preferred Stock

In October 2015, in connection with a registered direct offering, our board of directors authorized the designation and issuance of 10,000 shares and 4,750.0005 shares, respectively, of Series B Preferred Stock.

Subject to the terms and conditions of our Series B Preferred Stock and to customary adjustments to the conversion rate, each share of our Series B Preferred Stock is convertible into shares of our common stock at a conversion price equal to \$5.25 per share of common stock. Except as required by law, the Series B Preferred Stock generally will not have any voting rights. For a complete description of the terms of the Series B Preferred Stock, please see the certificate of designations, which is incorporated by reference into the registration statement of which this prospectus is a part.

The Series B Preferred may not be converted by the holder into shares of common stock unless the holder will, following such conversion, remain in compliance with certain beneficial ownership limitations. A holder will not have the right to convert any Series B Preferred if the holder (together with its affiliates and certain related parties) would hold more than 4.99% of the number of shares of our common stock outstanding, which limitation, subject to increase or decrease upon at least 60 days' notice by a holder, cannot be increased above 9.99%.

Series C Convertible Preferred Stock

In July 2016, in connection with a registered direct offering, our board of directors authorized the designation and issuance of 1,500 shares and 1,295 shares, respectively, of Series C Preferred Stock.

Subject to the terms and conditions of our Series C Preferred Stock and to customary adjustments to the conversion rate, each share of our Series C Preferred Stock is convertible into shares of our common stock at a conversion price equal to \$3.08375 per share of common stock. Except as required by law, the Series C Preferred Stock generally will not have any voting rights. For a complete description of the terms of the Series C Preferred Stock, please see the certificate of designations, which is incorporated by reference into the registration statement of which this prospectus is a part.

Table of Contents

The Series C Preferred may not be converted by the holder into shares of common stock unless the holder will, following such conversion, remain in compliance with certain beneficial ownership limitations. A holder will not have the right to convert any Series C Preferred if the holder (together with its affiliates and certain related parties) would hold more than 4.99% of the number of shares of our common stock outstanding, which limitation, subject to increase or decrease upon at least 60 days' notice by a holder, cannot be increased above 9.99%.

Series D Convertible Preferred Stock

The following summary of certain terms and provisions of our Series D Convertible Preferred Stock, or Series D Preferred, offered in this offering is subject to, and qualified in its entirety by reference to, the terms and provisions set forth in our certificate of designation of preferences, rights and limitations of Series D Preferred.

Designation. Subject to the limitations prescribed by our certificate of incorporation and under Delaware law, our board of directors is authorized to establish the number of shares constituting each series of preferred stock and to fix the designations, powers, preferences and rights of the shares of each of those series and the qualifications, limitations and restrictions of each of those series, all without any further vote or action by our stockholders. Our board of directors has designated _____ of the 2,000,000 authorized shares of preferred stock as Series D Preferred Stock. When issued, the shares of Series D Preferred Stock will be validly issued, fully paid and non-assessable.

Rank. The Series D Convertible Preferred Stock will rank on parity to our common stock.

Conversion; Beneficial Ownership Limitation Prohibiting Conversion. Each share of the Series D Preferred is convertible into shares of our common stock (subject to adjustment as provided in the related certificate of designation of preferences, rights and limitations) at any time at the option of the holder at a conversion price equal to the stated value of the Series D Preferred of \$1,000 divided by the public offering price of the common stock in this offering. Holders of Series D Preferred will be prohibited from converting Series D Preferred into shares of our common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 4.99% of the total number of shares of our common stock then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after such notice to us.

Liquidation Preference. In the event of our liquidation, dissolution or winding-up, holders of Series D Preferred will receive the same amount that a holder of common stock would receive if the Series D Preferred were fully converted into shares of our common stock at the conversion price (disregarding for such purposes any conversion limitations) which amounts shall be paid *pari passu* with all holders of common stock.

Voting Rights. Shares of Series D Preferred will generally have no voting rights, except as required by law and except that the affirmative vote of the holders of a majority of the then outstanding shares of Series D Preferred is required to, (a) alter or change adversely the powers, preferences or rights given to the Series D Preferred, (b) amend our certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders, or (c) increase the number of authorized shares of Series D Preferred.

Dividends. Shares of Series D Preferred will not be entitled to receive any dividends, unless and until specifically declared by our board of directors. The holders of the Series D Preferred will participate, on an as-if-converted-to-common stock basis, in any dividends to the holders of common stock.

Redemption. We are not obligated to redeem or repurchase any shares of Series D Preferred. Shares of Series D Preferred are not otherwise entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.

Exchange Listing. We do not plan on making an application to list the Series D Preferred on the NASDAQ Capital Market, any other national securities exchange or other nationally recognized trading system. Our common stock is listed the NASDAQ Capital Market under the symbol SCON.

Restrictive Covenant. We are restricted from selling additional equity securities for the 30 day period following the closing, subject to certain exceptions.

Table of Contents

Warrants to Purchase Common Stock

We currently have warrants outstanding representing the right to acquire 2,600,388 shares of our common stock at a weighted average exercise price of \$8.84 per share. Of such warrants, an aggregate of 407,825 warrants originally issued in our August 2013 financing include a price adjustment mechanism whereby the exercise price of such warrants will be automatically reduced, subject to limitations, to the extent we issue shares of our common stock, or equivalents, at a price lower than the then applicable exercise price of such warrants which is currently \$3.00. Accordingly, any offering price of the Units less than \$3.00 per Unit will cause the exercise price of the warrants originally issued in our August 2013 financing to be to such price.

Anti-Takeover Effects of Certain Provisions of Delaware Law and Our Charter Documents

The following is a summary of certain provisions of Delaware law, our certificate of incorporation and our bylaws. This summary does not purport to be complete and is qualified in its entirety by reference to the corporate law of Delaware and our certificate of incorporation and bylaws.

Effect of Delaware Anti-Takeover Statute. We are subject to Section 203 of the Delaware General Corporation Law, an anti-takeover law. In general, Section 203 prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years following the date that the stockholder became an interested stockholder, unless:

prior to that date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;

upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares of voting stock outstanding (but not the voting stock owned by the interested stockholder) those shares owned by persons who are directors and officers and by excluding employee stock plans in which employee participants do not have the right to determine whether shares held subject to the plan will be tendered in a tender or exchange offer; or

on or subsequent to that date, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 ²/₃% of the outstanding voting stock that is not owned by the interested stockholder.

Section 203 defines "business combination" to include the following:

any merger or consolidation involving the corporation and the interested stockholder;

any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;

subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or

the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation, or who beneficially owns 15% or more of the outstanding voting stock of the corporation at any time within a three-year period immediately prior to the date of determining whether such person is an interested stockholder, and any entity or person affiliated with or controlling or controlled by any of these entities or persons.

Table of Contents

Our Charter Documents. Our charter documents include provisions that may have the effect of discouraging, delaying or preventing a change in control or an unsolicited acquisition proposal that a stockholder might consider favorable, including a proposal that might result in the payment of a premium over the market price for the shares held by our stockholders. Certain of these provisions are summarized in the following paragraphs.

Classified Board of Directors. Pursuant to our certificate of incorporation, the number of directors is fixed by our board of directors. Our directors are divided into three classes, each class to serve a three-year term and to consist as nearly as possible of one-third of the total number of directors. Pursuant to our bylaws, directors elected by stockholders at an annual meeting of stockholders will be elected by a plurality of all votes cast.

No Stockholder Action by Written Consent. Our bylaws provide that a special meeting of stockholders may be called only by the chairman of the board, a majority of the entire board of directors or the president. Stockholders are not permitted to call, or to require that the board of directors call, a special meeting of stockholders. Moreover, the business permitted to be conducted at any special meeting of stockholders is limited to the business brought before the meeting pursuant to the notice of the meeting given. In addition, our certificate of incorporation provides that any action taken by our stockholders must be effected at an annual or special meeting of stockholders and may not be taken by written consent instead of a meeting. Our bylaws establish an advance notice procedure for stockholders to nominate candidates for election as directors or to bring other business before meetings of our stockholders.

Change in Control Agreements. A number of our executives have agreements with us that entitle them to payments in certain circumstances following a change in control.

Table of Contents

DESCRIPTION OF SECURITIES WE ARE OFFERING

We are offering 2,118,650 Class A Units each consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price equal to % of the public offering price of the Class A Units and 5,000 Class B Units each consisting of \$1,000 of Series D Preferred (convertible into 423.73 shares of common stock) and warrants to purchase 423.73 shares of common stock. The shares of common stock and warrants part of a Class A Unit and the Series D Preferred and warrants part of a Class B Unit are each immediately separable and will be issued separately in this offering. The rights and obligations associated with Class A Units and Class B Units consist only in the constituent parts of each such unit, except that the Company has approved the sale of the constituent parts as units on the terms and conditions described in this prospectus.

Common Stock and Series D Preferred

The material terms of our common stock, our Series D Preferred and our other capital stock are described in the section of this prospectus titled Description of Capital Stock beginning on page 22 of this prospectus.

Warrants to Purchase Common Stock

The material terms of the warrants to be issued are summarized below. This summary does not purport to be complete in all respects. This description is subject to and qualified entirely by the terms of the form of warrant filed as an exhibit to the registration statement of which this prospectus is a part.

The warrants to be issued with each Unit will have an exercise price of \$ per share (equal to % of the public offering price of the Class A Units) and shall have a term of exercise equal to .

The warrants may not be exercised by the holder to the extent that the holder, together with its affiliates, would beneficially own, after such exercise more than 4.99% of the shares of common stock then outstanding (subject to the right of the holder to increase or decrease such beneficial ownership limitation upon not less than 61 days prior notice provided that such limitation cannot exceed 9.99%).

The warrants are exercisable for cash or, solely in the absence of an effective registration statement or prospectus, by cashless exercise.

The exercise price of the warrants is subject to adjustment in the case of stock dividends or other distributions on shares of common stock or any other equity or equity equivalent securities payable in shares of common stock, stock splits, stock combinations, reclassifications or similar events affecting our common stock, and also, subject to limitations, upon any distribution of assets, including cash, stock or other property to our stockholders.

In addition, in the event we consummate a merger or consolidation with or into another person or other reorganization event in which our common shares are converted or exchanged for securities, cash or other property, or we sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding common shares, then following such event, the holders of the warrants will be entitled to receive upon exercise of the warrants the same kind and amount of securities, cash or property which the holders would have received had they exercised the warrants immediately prior to such fundamental transaction. Any successor to us or surviving entity shall assume the obligations under the warrants.

Prior to the exercise of any warrants to purchase common stock, holders of the warrants will not have any of the rights of holders of the common stock purchasable upon exercise, including voting rights, however, the holders of the

warrants will have certain rights to participate in distributions or dividends paid on our common stock to the extent set forth in the warrants.

In addition, the warrants provide that if, at any time while such warrants are outstanding, we (1) consolidate or merge with or into another corporation, (2) sell all or substantially all of our assets or (3) are subject to or complete a tender or exchange offer pursuant to which holders of our common stock are permitted to tender or exchange their

Table of Contents

shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (4) effect any reclassification, reorganization or recapitalization of our common stock or any compulsory share exchange pursuant to which our common stock is converted into or exchanged for other securities, cash or property, or (5) engage in one or more transactions with another party that results in that party acquiring more than 50% of our outstanding shares of common stock (each, a Fundamental Transaction), then the holder of such warrants shall have the right thereafter to receive, upon exercise of the warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of warrant shares then issuable upon exercise of the warrant, and any additional consideration payable as part of the Fundamental Transaction. Any successor to us or the surviving entity shall assume the obligations under the warrant.

The provisions of the warrants may be amended if we obtain the written consent of holders representing not less than a majority of shares of our common stock then exercisable under the warrants (in which case such amendments shall be binding on all holders of the warrants). However, the number of shares of our common stock exercisable, the exercise price or the exercise period may not be amended without the written consent of the holder of each such warrant.

We do not plan on applying to list the Series D Preferred or any of the warrants on the NASDAQ Capital Market, any other national securities exchange or any other nationally recognized trading system.

Table of Contents**PLAN OF DISTRIBUTION**

We engaged H.C. Wainwright & Co., LLC (H.C. Wainwright or the placement agent) to act as our exclusive placement agent to solicit offers to purchase the securities offered by this prospectus. H.C. Wainwright is not purchasing or selling any units, nor are they required to arrange for the purchase and sale of any specific number or dollar amount of units, other than to use their reasonable best efforts to arrange for the sale of the Units by us. Therefore, we may not sell the entire amount of the Class A Units and Class B Units (the Units) being offered. We will enter into a securities purchase agreement directly with institutional investors in this offering. We will not enter into a securities purchase agreement with non-institutional investors and such investors shall rely solely on this prospectus in connection with the purchase of securities in this offering.

H.C. Wainwright may engage one or more sub-placement agents or selected dealers to assist with the offering.

Upon the closing of this offering, we will pay the placement agent a cash transaction fee equal to 7% of the gross proceeds to us from the sale of the Units in the offering and a management fee equal to 1% of the gross proceeds of the offering. We will also reimburse the Placement Agent \$100,000 for its legal fees and expenses incurred in connection with this offering and reimburse up to \$50,000 of the Placement Agent's accountable expenses.

The following table shows the per unit and total placement agent fees we will pay in connection with the sale of the securities in this offering, assuming the purchase of all of the securities we are offering.

Per Class A Unit placement agent cash fees	\$
Per Class B Unit placement agent cash fees	\$
Total	\$

We estimate the total expenses of this offering, which will be payable by us, excluding the placement agent fees, will be approximately \$. After deducting the placement agent fees and our estimated offering expenses, we expect the net proceeds from this offering to be approximately \$ million.

In addition, upon commencement of this offering we will grant a right of first refusal to the placement agent pursuant to which it has the right to act as the exclusive advisor, manager or underwriter or agent, as applicable, if the Company or its subsidiaries sell or acquire a business, finance any indebtedness using an agent, or raise capital through a public or private offering of equity or debt securities at any time prior to the twelve month anniversary of the date of commencement of sales in this offering.

Table of Contents

The placement agent may be deemed to be an underwriter within the meaning of Section 2(a)(11) of the Securities Act and any fees received by it and any profit realized on the sale of the securities by it while acting as principal might be deemed to be underwriting discounts or commissions under the Securities Act. The placement agent will be required to comply with the requirements of the Securities Act and the Exchange Act of 1934, as amended (the Exchange Act), including, without limitation, Rule 10b-5 and Regulation M under the Exchange Act. These rules and regulations may limit the timing of purchases and sales of our securities by the placement agent. Under these rules and regulations, the placement agent may not (i) engage in any stabilization activity in connection with our securities; and (ii) bid for or purchase any of our securities or attempt to induce any person to purchase any of our securities, other than as permitted under the Exchange Act, until they have completed their participation in the distribution.

Other Relationships

The placement agent has performed investment banking services for us in the past, for which it has received customary fees and expenses. The placement agent may, from time to time, engage in transactions with or perform services for us in the ordinary course of its business and may continue to receive compensation from us for such services.

Determination of offering price

The public offering price of the Units we are offering and the exercise price and other terms of the warrants were negotiated between us and the investors, in consultation with the placement agent based on the trading of our common stock prior to the offering, among other things. Other factors considered in determining the public offering price of the Units we are offering and the exercise price and other terms of the warrants include the history and prospects of the Company, the stage of development of our business, our business plans for the future and the extent to which they have been implemented, an assessment of our management, general conditions of the securities markets at the time of the offering and such other factors as were deemed relevant.

Lock-up Agreements

We have agreed with the placement agent to be subject to a lock-up period of days following the date of this prospectus. This means that, during the applicable lock-up period, we may not offer for sale, contract to sell, or sell any shares of our common stock or any securities convertible into, or exercisable or exchangeable for, shares of our common stock subject to certain customary exception such as issuing stock options to directors, officers, employees and consultants under our existing plans. The placement agent may, in its sole discretion and without notice, waive the terms of any of these lock-up agreements.

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is Computershare.

Indemnification

We have agreed to indemnify the placement agent against certain liabilities, including liabilities under the Securities Act of 1933, or to contribute to payments the placement agent may be required to make with respect to any of these liabilities.

Table of Contents

LEGAL MATTERS

Certain legal matters relating to the validity of our securities offered by this prospectus will be passed upon for us by Manatt, Phelps & Phillips, LLP, Los Angeles, California. Ellenoff Grossman & Schole LLP, New York, New York is counsel for the placement agent in connection with this offering. Certain partners of Manatt, Phelps & Phillips, LLP or their affiliates own shares of our common shares representing less than 0.5% of our outstanding common stock as of the date of this prospectus supplement.

EXPERTS

The consolidated financial statements of Superconductor Technologies Inc., as of December 31, 2015 and 2014, and for each of the three years in the period ended December 31, 2015, incorporated in this prospectus by reference to the Annual Report on Form 10-K of Superconductor Technologies Inc. for the year ended December 31, 2015 have been so incorporated in reliance on the report (which contains an explanatory paragraph related to the company's ability to continue as a going concern) of Marcum, LLP, Independent Registered Public Accounting Firm, given on the authority of said firm as experts in auditing and accounting.

WHERE YOU CAN FIND MORE INFORMATION

We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any document we file with the SEC at the SEC's Public Reference Room at 100 F Street, N.E., Washington D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the Public Reference Room. The SEC also maintains a web site that contains reports, proxy and information statements, and other information regarding registrants that file electronically with the SEC at <http://www.sec.gov>. In addition, we maintain a web site that contains information about us at <http://www.suptech.com>. The information contained on or that may be obtained from our website is not, and shall not be deemed to be, a part of this prospectus.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

This prospectus omits some information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits included in the registration statement of which this prospectus is a part for further information about us and the securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements.

The SEC allows us to incorporate by reference information we file with it, which means that we can disclose important information to you by referring you to other documents. The information incorporated by reference is considered to be a part of this prospectus. Information contained in this prospectus supersedes information incorporated by reference that we have filed with the SEC prior to the date of this prospectus.

We incorporate by reference the following documents listed below (excluding any document or portion thereof to the extent such disclosure is furnished and not filed):

Our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed with the SEC on March 30, 2016, as amended by Amendment No. 1 to our Annual Report on Form 10-K filed with the SEC

on July 22, 2016;

Our Quarterly Reports on Form 10-Q for the fiscal quarter ended April 2, 2016, as filed with the SEC on May 13, 2016, for the fiscal quarter ended July 2, 2016, as filed with the SEC on August 15, 2016, and for the fiscal quarter ended October 1, 2016, as filed with the SEC on November 15, 2016;

Our Definitive Proxy Statements on Schedule 14A, filed with the SEC on May 16, 2016 and September 20, 2016; and

Information in the documents referred to above that are incorporated by reference in this prospectus that were filed prior to the 1-12 reverse split of our common stock that was effective on March 11, 2013 and the 1-for-15 reverse stock split of our common stock that was effective on July 18, 2016 do not reflect the effects of such reverse stock splits.

Table of Contents

Our Current Reports on Form 8-K filed with the SEC on April 29, 2016, June 24, 2016, July 18, 2016, July 27, 2016, August 2, 2016 and October 28, 2016.

These documents contain important information about us, our business and our financial condition. You may request a copy of these filings, at no cost, by writing or telephoning us at:

Superconductor Technologies Inc.

9101 Wall Street, Suite 1300

Austin, TX 78754

(512) 334-8900

Table of Contents

2,118,650 Class A Units each consisting of one share of Common Stock and a Warrant

to purchase one share of Common Stock

5,000 Class B Units each consisting of \$1,000 of Series D Convertible Preferred Stock (convertible into 423.73 shares of Common Stock) and Warrants to purchase

423.73 shares of Common Stock

(2,118,650 shares of Common Stock Underlying the Series D Convertible Preferred Stock

and 4,237,300 shares underlying the Warrants)

Superconductor Technologies Inc.

Preliminary Prospectus

Rodman & Renshaw

a unit of H.C. Wainwright & Co.

, 2016

Table of Contents**PART II****INFORMATION NOT REQUIRED IN PROSPECTUS****ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION**

The following table sets forth the various expenses to be incurred in connection with the sale and distribution of our securities being registered hereby, all of which will be borne by us. All amounts shown are estimates except the SEC registration fee and the FINRA filing fee.

SEC registration fee	\$ 4,346.25
FINRA filing fee	3,500
Printing and engraving expenses	20,000
Legal fees and expenses	75,000
Accounting fees and expenses	20,000
Transfer Agent Fees	1,000
Miscellaneous fees and expenses	2,500
 Total	 \$ 126,346.25

* To be completed by amendment.

ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS

Section 145 of the Delaware General Corporation Law, or the Delaware Law, provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys fees), judgments, fines and amounts paid in settlement in connection with specified actions, suits or proceedings, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation or a derivative action), if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe their conduct was unlawful. A similar standard is applicable in the case of derivative actions, except that indemnification only extends to expenses (including attorneys fees) incurred in connection with defense or settlement of such action, and the statute requires court approval before there can be any indemnification where the person seeking indemnification has been found liable to the corporation. Under Section 145, a corporation shall indemnify an agent of the corporation for expenses actually and reasonably incurred if and to the extent such person was successful on the merits in a proceeding or in defense of any claim, issue or matter therein.

Section 145 of the Delaware Law provides that it is not exclusive of other indemnification that may be granted by a corporation's charter, bylaws, disinterested director vote, stockholders vote, agreement or otherwise. The limitation of liability contained in our restated certificate of incorporation, as amended, and the indemnification provision included in our amended and restated bylaws, as amended, are consistent with Delaware Law Sections 102(b)(7) and 145. We have purchased directors and officers liability insurance.

Section 145 of the Delaware Law authorizes the court to award, or a corporation's board of directors to grant, indemnity to directors and officers in terms sufficiently broad to permit such indemnification under certain circumstances for liabilities (including reimbursement for expenses incurred) arising under the Securities Act of 1933. Our restated certificate of incorporation, as amended, and amended and restated bylaws, as amended, provide for indemnification of our directors, officers, employees and other agents to the maximum extent permitted by the Delaware Law. In addition, we have entered into indemnification agreements with our officers and directors.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling our company pursuant to such provisions, we have been informed that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in such Act and is therefore unenforceable.

Table of Contents

ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES

On July 27, 2016, the Company issued an aggregate of 535,062 warrants to purchase common stock at an exercise price of \$3.00 per share and exercisable during the period following the six month anniversary of the date of issuance until the five and a half year anniversary of the date of issuance. The warrants were issued to purchasers of the Company's common stock or Series C Preferred Stock in the Company's concurrent registered offering in July 2016. In addition, we issued to H.C. Wainwright & Co., LLC, the placement agent, five year warrants to purchase a number of shares of our common stock equal to 7% of the aggregate number of shares of common stock (including underlying the Series C Preferred Stock) sold to the investors in this offering with such warrants having an exercise price of \$3.855 (125% of the public offering price per share of common stock). The warrants and the shares of our common stock issuable upon the exercise of the warrants were offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and Rule 506 promulgated thereunder.

On October 14, 2015, in connection with a registered offering, the Company issued to Rodman & Renshaw, a unit of H.C. Wainwright & Co., who acted as placement agent in such registered offering, five-year warrants equal to 5% of the aggregate number of shares of common stock part of the Class A Units and the common stock convertible under the Series B Preferred Stock part of the Class B Units sold in the offering, each at an exercise price of \$6.56 per share (125% of the public offering price of the Class A Units). The issuance of the foregoing warrants were issued in transactions exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder.

On March 25, 2015, the Company issued an aggregate of 102,093 investor warrants to purchase common stock at an exercise price of \$24.49 per share, exercisable until five years and six months from the date of issuance. The warrants are exercisable for cash or, solely in the absence of an effective registration statement or prospectus, by cashless exercise. The exercise of the warrants is subject to certain beneficial ownership and other limitations set forth in the warrants. Such warrants were issued in a private placement that was conducted concurrently with a registered offering of 204,186 shares of its common stock. In connection with such registered offering, the Company issued to the placement agent in such registered offering five-year warrants equal to 5% of the aggregate number of shares of common stock sold in the registered offering, at an exercise price of \$30.61. The issuance of the foregoing warrants were issued in transactions exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder.

On February 14, 2015, the Company entered into Warrant Exercise Agreements with certain holders of outstanding warrants to purchase an aggregate of 61,124 shares of common stock in the Company. The warrants were certain of the Term B warrants originally issued as part of an underwritten public offering by the Company that closed on August 9, 2013. In connection with the Warrant Exercise Agreements, the Company engaged H.C. Wainwright & Co., LLC to act as the Company's financial advisor and, as part of the compensation to such advisor, issued a five-year warrant to purchase five percent (5%) of the number of shares so exercised at an exercise price equal to 110% of the closing price of the common stock on February 13, 2015. The issuance of the foregoing warrants were issued in transactions exempt from registration pursuant to Section 4(a)(2) under the Securities Act.

On August 5, 2013, in connection with an underwritten registered offering, the Company issued to Ladenburg Thalmann & Co. Inc., who acted as underwriter in such registered offering, three-year warrants equal to 3.0% of the number of units sold in the offering at an exercise price equal to \$33.73 (125% of the public offering price per Class A Unit sold in the offering). The issuance of the foregoing warrants were issued in transactions exempt from registration pursuant to Section 4(a)(2) under the Securities Act.

ITEM 16. EXHIBITS

(a) *Exhibits.* The exhibits are incorporated by reference from the Exhibit Index attached hereto.

ITEM 17. UNDERTAKINGS

The undersigned registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

Table of Contents

- (a) To include any prospectus required by Section 10(a)(3) of the Securities Act;

 - (b) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the effective registration statement;

 - (c) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.
- (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
- (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
- (4) That each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. *Provided, however,* that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.
- (5) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser in the initial distribution of the securities: the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: (i) any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; (ii) any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; (iii) the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and (iv) any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the indemnification provisions described herein, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In

the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

Table of Contents

The undersigned registrant hereby undertakes that:

(1) For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus as filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act of 1933 shall be deemed to be part of this registration statement as of the time it was declared effective.

(2) For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Amendment No. 2 to Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Austin, State of Texas, on this 7th day of December, 2016.

SUPERCONDUCTOR TECHNOLOGIES
INC.

By: /s/ Jeffrey A. Quiram

Jeffrey A. Quiram

President and Chief Executive Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No. 2 to Registration Statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated.

/s/ Jeffrey A. Quiram	President, Chief Executive Officer and Director (Principal Executive Officer)	December 7, 2016
Jeffrey A. Quiram		
/s/ William J. Buchanan	Chief Financial Officer	December 7, 2016
William J. Buchanan	(Principal Accounting Officer) (Principal Financial Officer)	
/s/ *	Chairman of the Board	December 7, 2016
Martin A. Kaplan		
/s/ *	Director	December 7, 2016
Lynn J. Davis		
/s/ *	Director	December 7, 2016
Dan L. Halvorson		

*By: /s/ Jeffrey A. Quiram
Jeffrey A. Quiram

Attorney-in-fact

S-1

Table of Contents**EXHIBIT INDEX****EXHIBIT****NUMBER****DESCRIPTION OF DOCUMENT**

3.1	Restated Certificate of Incorporation of Registrant as amended through March 1, 2006. (14)
3.2	Certificate of Amendment of Restated Certificate of Incorporation of Registrant, filed March 11, 2013. (21)
3.3	Amended and Restated Bylaws of Registrant. (14)
3.4	Amendment adopted March 29, 2010 to Amended and Restated Bylaws of Registrant. (15)
3.5	Amendment adopted October 28, 2013 to Amended and Restated Bylaws of Registrant. (23)
4.1	Form of Common Stock Certificate. (13)
4.2	Form of Series B Preferred Stock Certificate. (31)
4.3	Certificate of Designations of Registrant of Series A Convertible Preferred Stock of Registrant filed November 13, 2007. (12)
4.4	Certificate of Designations of Registrant of Series B Convertible Preferred Stock of Registrant and form of Series B Convertible Preferred Stock Certificate. (31)
4.5	Form of Warrant to Purchase Common Stock issued by Registrant on February 22, 2012. (16)
4.6	Form of Warrant to Purchase Common Stock issued by Registrant on November 26, 2012. (19)
4.7	Form of Warrant to Purchase Common Stock issued by Registrant on December 18, 2012. (20)
4.8	Forms of Series A and Series B Warrants to Purchase Common Stock issued by Registrant on April 26, 2013. (22)
4.9	Form of Warrant to Purchase Common Stock issued by Registrant on August 9, 2013. (24)
4.10	Form of Underwriter's Warrant issued by Registrant on August 5, 2013. (32)
4.11	Form of Warrant Exercise Agreement dated February 14, 2015 and Financial Advisor Warrant. (25)
4.12	Form of Warrant to Purchase Common Stock issued by Registrant on March 25, 2015, pursuant to the Purchase Agreement. (27)
4.13	Form of Placement Agent Warrant to Purchase Common Stock issued by Registrant on March 25, 2015. (27)
4.14	Form of Series [A][B] Common Stock Purchase Warrant issued by Registrant on October 14, 2015. (28)
4.15	Form of Placement Agent Warrant to Purchase Common Stock issued by Registrant on October 14, 2015. (29)
4.16	Form of Series C Preferred Stock Certificate.(33)

Edgar Filing: SUPERCONDUCTOR TECHNOLOGIES INC - Form S-1/A

4.17	Certificate of Designations of Registrant of Series C Convertible Preferred Stock of Registrant. (33)
4.18	Form of Warrant to Purchase Common Stock issued by Registrant on August 2, 2016. (33)
4.19	Form of Placement Agent Warrant to Purchase Common Stock issued by Registrant on August 2, 2016. (33)
4.20	Securities Purchase Agreement, dated as of July 27, 2016, between Registrant and the investors party thereto. (33)
4.21	Form of Series D Preferred Stock Certificate. *
4.22	Certificate of Designations of Registrant of Series D Convertible Preferred Stock of Registrant.*
4.23	Form of Securities Purchase Agreement. v
4.24	Form of Warrant to Purchase Common Stock. *
5.1	Opinion of Manatt, Phelps & Phillips, LLP. v
10.1	Form of Change in Control Agreement dated March 28, 2003. (1)***
10.2	Form of Amendment No. 1 to Change in Control Agreement dated as of May 24, 2005. (7)***

Table of Contents

10.3	Form of Amendment No. 2 to Change in Control Agreement dated as of December 31, 2006. (9)***
10.4	Patent License Agreement by and between Registrant and Lucent Technologies GRL LLC. (2)**
10.5	License Agreement between Registrant and Sunpower dated May 2, 2005. (3)**
10.6	Employment Agreement between Registrant and Jeffrey Quiram dated as of February 14, 2005. (4)***
10.7	Amendment to Employment Agreement between Registrant and Jeffrey Quiram dated as of December 31, 2006. (9)***
10.8	2003 Equity Incentive Plan As Amended May 25, 2005. (6)***
10.9	Form of Notice of Grant of Stock Options and Option Agreement for 2003 Equity Incentive Plan. (4)***
10.10	Management Incentive Plan (July 24, 2006). (8)***
10.11	Compensation Policy for Non-Employee Directors dated March 18, 2005. (5)***
10.12	Form of Director and Officer Indemnification Agreement. (26)***
10.13	Lease Agreement between the Registrant and Prologis Texas III LLC dated December 5, 2011. (17)
10.14	First Amendment to Lease Agreement between the Registrant and Prologis Texas III LLC dated August 23, 2012. (18)
10.15	Second Amendment to Lease Agreement between Registrant and Prologis Texas III LLC dated July 18, 2014. (26)
10.16	Agreement between Registrant and Hunchun BaoLi Communication Co., Ltd. (BAOLI) dated August 17, 2007. (10)
10.17	First Amendment to Agreement between Registrant and BAOLI dated November 1, 2007. (11)
10.18	Second Amendment to Agreement between Registrant and BAOLI dated January 7, 2008. (11)
10.19	Framework Agreement between Registrant and BAOLI dated November 8, 2007. (11)
10.20	Sino-Foreign Equity Joint Venture Contract between Superconductor Investments (Mauritius) Limited and BAOLI dated December 8, 2007 (Exhibit A to Framework Agreement with BAOLI). (11)
10.21	Form of Technology and Trademark License Agreement between Superconductor Investments (Mauritius) Limited, Registrant and BAOLI (Exhibit B to Framework Agreement). (11)
10.22	2013 Equity Incentive Plan adopted October 25, 2013, and forms of Award Agreements. (30) ***
21	List of Subsidiaries. (34)
23.1	Consent of Marcum, LLP, Independent Registered Public Accounting Firm. v
23.2	Consent of Manatt, Phelps & Phillips, LLP (included in Exhibit 5.1). v
24.1	Power of Attorney is contained on the signature page. *

(1) Incorporated by reference from Registrant's Quarterly Report on Form 10-Q for the quarter ended March 29, 2003, filed May 13, 2003.

(2)

Edgar Filing: SUPERCONDUCTOR TECHNOLOGIES INC - Form S-1/A

- Incorporated by reference from Registrant's Annual Report on Form 10-K for the year ended December 31, 2003, filed March 11, 2004.
- (3) Incorporated by reference from Registrant's Quarterly Report on Form 10-Q for the quarter ended October 2, 2004, filed November 10, 2004.
 - (4) Incorporated by reference from Registrant's Annual Report on Form 10-K for the year ended December 31, 2004, filed March 16, 2005.
 - (5) Incorporated by reference from Registrant's Quarterly Report on Form 10-Q for the quarter ended April 2, 2005, filed May 6, 2005.
 - (6) Incorporated by reference from Registrant's Current Report on Form 8-K filed May 27, 2005.
 - (7) Incorporated by reference from Registrant's Annual Report on Form 10-K for the year ended December 31, 2005, filed March 8, 2006.

Table of Contents

- (8) Incorporated by reference from Registrant's Current Report on Form 8-K filed July 28, 2006.
- (9) Incorporated by reference from Registrant's Annual Report on Form 10-K for the year ended December 31, 2006, filed April 2, 2007.
- (10) Incorporated by reference from Registrant's Quarterly Report on Form 10-Q for the quarter ended September 29, 2007, filed November 13, 2007.
- (11) Incorporated by reference from Registrant's Annual Report on Form 10-K for the year ended December 31, 2007, filed March 27, 2008.
- (12) Incorporated by reference from Registrant's Current Report on Form 8-K/A filed February 25, 2008.
- (13) Incorporated by reference as Exhibit 4.1 to Registrant's Form 10-K filed March 28, 2014.
- (14) Incorporated by reference from Registrant's Annual Report on Form 10-K for the year ended December 31, 2009, filed March 17, 2010.
- (15) Incorporated by reference from Registrant's Current Report on Form 8-K filed April 2, 2010.
- (16) Incorporated by reference from Registrant's Current Report on Form 8-K/A filed February 22, 2012.
- (17) Incorporated by reference from Registrant's Annual Report on Form 10-K for the year ended December 31, 2011, filed March 30, 2012.
- (18) Incorporated by reference from Registrant's Quarterly Report on Form 10-Q for the quarter ended September 29, 2012, filed November 13, 2012.
- (19) Incorporated by reference from Registrant's Current Report on Form 8-K filed November 27, 2012.
- (20) Incorporated by reference from Registrant's Current Report on Form 8-K filed December 19, 2012.
- (21) Incorporated by reference from Registrant's Current Report on Form 8-K filed March 14, 2013.
- (22) Incorporated by reference from Registrant's Current Report on Form 8-K filed April 30, 2013.
- (23) Incorporated by reference from Registrant's Current Report on Form 8-K filed October 31, 2013.
- (24) Incorporated by reference as Exhibit 4.9 to Registrant's Form S-1/A filed August 2, 2013.
- (25) Incorporated by reference from Registrant's Current Report on Form 8-K filed February 17, 2015.
- (26) Incorporated by reference from Registrant's Annual Report on Form 10-K for the year ended December 31, 2014, filed March 12, 2015.
- (27) Incorporated by reference from Registrant's Current Report on Form 8-K filed March 24, 2015.
- (28) Incorporated by reference as Exhibit 4.11 to Registrant's Form S-1/A filed October 6, 2015.
- (29) Incorporated by reference as Exhibit 4.12 to Registrant's Form S-1/A filed October 6, 2015.
- (30) Incorporated by reference as Exhibit A to Registrant's Schedule 14A filed October 31, 2013.
- (31) Incorporated by reference from Registrant's Current Report on Form 8-K filed October 13, 2015.
- (32) Incorporated by reference as Exhibit 4.10 to Registrant's Form S-1/A filed July 30, 2013.
- (33) Incorporated by reference from Registrant's Current Report on Form 8-K filed August 2, 2016.
- (34) Incorporated by reference from Registrant's Annual Report on Form 10-K filed March 30, 2016.

v Filed herewith.

* Previously filed.

** Confidential treatment has been previously granted for certain portions of these exhibits.

*** This exhibit is a management contract or compensatory plan or arrangement.